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Abstract 
Introduction: Ionising radiation can cause DNA double strand breaks (DSB), that result in 
chromosomal aberrations if un- or mis-repaired. Individuals with compromised DNA damage 
repair mechanisms display increased chromosomal radiosensitivity. The G0-micronucleus 
assay (MN assay) and the γ-H2AX assay are two assays used in radiobiology to study DNA 
DSB and repair. 
Breast cancer is the leading cancer amongst South African women, with a lifetime risk of 1 in 
34. Since most cancer patients in South Africa present with late-stage disease, 
chemotherapy and radiotherapy are commonly-used treatments. Several international 
studies have shown breast cancer patients to be more chromosomally radiosensitive than 
healthy controls. These studies have not been confirmed on a cancer population living in 
South Africa.  
Cervical cancer is the second most common cancer in South Africa; however, it is the leading 
cancer amongst black women with a lifetime risk of 1/35 compared to 1/82 in white 
women. Studies show a genetic link to cervical cancer susceptibility and DNA damage repair 
genes. International studies on radiation-induced DNA damage in lymphocytes of cervical 
cancer patients remain inconclusive and have never been performed on a South African 
population. Cervical cancer is caused by infection with the Human Papilloma Virus (HPV). 
Human Immunodeficiency Virus (HIV), HPV and cervical cancer are epidemiologically linked. 
Due to the high rate of HIV in South Africa, a significant proportion of cervical cancer 
patients receiving radiotherapy treatment will be HIV-positive. Studies show an effect of HIV 
on chromosomal radiosensitivity, however this has not been confirmed on a cancer 
population. The MN assay on the biopsies and exfoliated cervical cells of cervical cancer 
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patients could be used as a predictive test for response to radiotherapy. The overall aim was 
to study chromosomal radiosensitivity in South African cervical and breast cancer patients. 
Materials and methods: Chromosomal radiosensitivity of lymphocytes of cervical and breast 
cancer patients was examined using the MN assay with the Metafer 4 of Metasystems. 
Different scoring methods for the Metafer system were compared to each other. The effect 
of HIV, HPV, ethnicity, clinical parameters and age on micronuclei (MN) values in 
lymphocytes was investigated. The MN assay was attempted on cells from cervical biopsies 
and exfoliated cervical cells. The γ-H2AX was performed on the lymphocytes of a group of 
cervical cancer patients. 
Results: A new scoring method for the Metafer 4 system that is more reliable in patients 
with late-stage disease was introduced. Cervical cancer patients had significantly higher MN 
values with HIV patients having the highest values. HPV, clinical parameters and age had a 
limited effect on MN values. The MN assay was unsuccessful on biopsies and exfoliated 
cervical cells of cervical cancer patients. There was no difference in double strand break 
induction and repair between cervical cancer patients and controls. In breast cancer 
patients, ethnicity had an effect on MN values, with only white breast cancer patients 
having significantly higher MN counts. 
Conclusion: The study showed increased chromosomal radiosensitivity in cervical cancer 
and white breast cancer patients. Results highlight how such studies are important within 
the South African context, where factors like HIV, disease stage and ethnicity can have an 
effect on chromosomal radiosensitivity and where unique genes/polymorphisms may play a 
role in cancer risk. 
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1 Introduction 
1.1 Ionising radiation and radiobiology 
1.1.1 Types of ionising radiation 
Ionising radiation is radiation that causes a molecule to lose an electron upon absorption 
because its energy exceeds the energy of the intra-molecular bindings of the molecule. 
Ionising radiations can be divided into electromagnetic and particle radiations. X-rays and 
gamma (γ) rays are two types of electromagnetic radiations. Examples of particle radiations 
include electrons, protons, neutrons and α-particles. Ionising radiation can be further 
classified based on linear energy transfer (LET). LET is the amount of energy deposited along 
the path of the ionising particle per unit of path length. Since X- and γ-rays have ionisations 
that are sparse and infrequent, they are considered low LET radiation. Low LET radiations 
are commonly used in medical applications. Particle radiations like α-particles and neutrons 
are considered high LET radiations as they cause frequent ionisations over a short distance. 
The same dose of radiation with different LET do not produce the same biological effect. 
Relative biological effect (RBE) is the term used to define the biological effects produced by 
different types of radiation. For example, a dose of 1 Gray (Gy) of X-ray results in 
approximately 1000 single and isolated ionisation tracks, whereas 1 Gy with α-particles 
results in approximately 4 tracks, but the ionisations are more dense, complex and 
damaging, causing α-particles to have a higher RBE. 
1.1.2 Effect of ionising radiation on the cell 
The effect of ionising radiation on a cell can be direct or indirect. Direct action is when the 
energy of the radiation is deposited directly into a critical biological macromolecule such as 
DNA, RNA or proteins. Indirect action is when ionisations occur elsewhere in the cell but still 
 2 
 
affect critical targets. Indirect action primarily occurs through ionisation of H2O which forms 
H atoms and hydroxyl radicals. These radicals are highly reactive and account for 70% of 
DNA damage induced by radiation (Jeggo and Lavin, 2009).  
Damage to DNA can have serious consequences as it regulates all cellular activity. 5 major 
categories of DNA damage can occur when a cell is targeted by ionising radiation: 1) Base 
damage: change or loss of a base on the DNA strand; 2) Crosslinks: links are formed 
between two complementary strands of DNA; 3) Destruction of sugars: pentose sugars 
forming the backbone of DNA; 4) Single strand breaks (SSB): breaks on one strand of DNA; 
and 5) Double strand breaks: breaks in both strands of DNA. These different types of 
damage can occur separately or together which results in complex DNA damage. Once DNA 
damage occurs in a cell, a number of proteins detect the damage (sensors) and initiate a 
series of responses (signalers). These responses include apoptosis, alterations of gene 
expression, changes in cell cycle check points and DNA damage repair.   
1.1.3 DNA damage repair 
There are 5 main types of DNA damage repair that can occur in mammalian cells depending 
on the type of damage, cell type and phase of the cell cycle. These include 1) Base excision 
repair (BER); 2) Nucleotide excision repair (NER); 3) Mismatch repair (MMR); 4) Homologous 
recombination (HR) and 5) Non-homologous endjoining (NHEJ). 
BER:  A damaged base is recognised and removed by DNA glycosylases.  
Apurinic/Apyrimidinic endonucleases (e.g. APE1) incise the DNA strand next to the baseless 
sugar residue and it is replaced with a new nucleotide by DNA polymerase β. The nick is 
ligated by the ligase 3/ X-ray cross complementing 1 (XRCC1) complex (Georgakilas, 2008). 
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Mutations in this pathway have been shown to be associated with colon cancer (Karahalil et 
al., 2012). 
NER: There are 2 NER pathways: global genome repair (GGR) which removes DSB across the 
whole genome; and transcription-coupled repair (TCR) which only removes DSB in 
transcribed genes. These methods are the same except for recognition and involve the 
following: 1) recognition of the lesion by Xeroderma pigmentosum complementation group 
C (XPC) - Xeroderma pigmentosum complementation group E (XPE) protein complex in GGR 
or RNA polymerase with Cockayne syndrome group A (CSA) and Cockayne syndrome group 
B (CSB) in TCR; 2) DNA incision by Xeroderma pigmentosum complementation group G 
(XPG) and Xeroderma pigmentosum complementation group F (XPF) - Excision repair cross 
complementing protein 1 (ERCC1) that bracket and remove the lesion of 24-32 nucleotides 
in length; 3) Filling in of the gap by polymerases and Proliferating cell nuclear antigen 
(PCNA) followed by DNA ligation. Mutations in this pathway lead to disorders such as 
Xeroderma Pigmentosum (Hall and Giacci, 2012).   
MMR: Replication errors can result in mismatched base pairs. Proteins MutS homolog 
(MSH) recognise and bind to the mismatched pairs, which results in recruitment of MutL 
homolog 1 (MLH1) and Post meiotic segregration increased 2 (PMS2). The damaged region 
is cleaved and removed by exonucleases. The single strand gap is then filled in by DNA 
polymerase α (Houtgraaf et al., 2006). Mutations in this pathway are associated with 
hereditary nonpolyposis colorectal cancer and Lynch syndrome, where there is an increased 
risk for colon and other cancers (Kaz and Brentnall, 2006, Goodenberger and Lindor, 2011). 
HR: This pathway is involved in the repair of DSB. It is mostly error free as it relies on 
undamaged templates to restore any lost sequence information. It only functions in the late 
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S and G2 phase of the cell cycle when a sister chromatid is available. Sensors detect the DNA 
double strand break and Ataxia telangiectasia mutated (ATM) and Ataxia telangiectasia and 
Rad3-related (ATR) (protein kinases belonging to the phosphatidylinositol-3-kinase-related 
kinase (PIKK family)) are recruited to the damaged site. ATM recruits Breast cancer 1 
(BRCA1) by phosphorylating a protein, Histone subtype H2A isoform X (H2AX), which in turn 
regulates the Nijmegen breakage syndrome 1 (NBS1)/ Meiotic recombination 11 homolog 
(MRE11)/RAD50 homolog (RAD50) complex. MRE11 resects the DNA resulting in a 3’ single 
stranded DNA that serves as a binding site for RAD51 recombinase (RAD51). BRCA2, which is 
recruited to the site by BRCA1, facilitates RAD51 being loaded onto single strand overhangs 
coated with Replication Protein A (RPA) which keeps the single DNA strand from binding to 
itself. RAD52 homolog (RAD52) is also recruited to the site to prevent any exonucleolytic 
degradation. RAD54 homolog (RAD54) uses its ATPase activity to unwind the double-
stranded molecule. The two invading ends act as primers for DNA synthesis and thereafter 
holiday junctions (interwound DNA strands) are resolved by Crossover junction 
endonuclease EME1 (EME1) and MUS81 structure-specific endonuclease subunit (MUS81) 
(Shibata and Jeggo, 2014). Mutations in the ATM gene of this pathway cause the syndrome 
Ataxia Telangiectasia, a neurodegenerative disorder where patients show increased 
susceptibility to cancer and high toxicity to radiation therapy (Jeggo and Lavin, 2009). The 
HR pathway is illustrated in figure 1.1. 
NHEJ: This pathway, also involved in double strand break repair, is more error-prone than 
HR as it does not rely on a sister chromatid to act as a template for homologous 
recombination. The first step is the recruitment of the Ku heterodimer (70-kDA and 83-kDA 
subunits), which has a high affinity for DNA, to the damaged site. The bound heterodimer 
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recruits DNA-dependent protein kinase catalytic subunit (DNA-PK), causing assembly of 
DNA-PK at the ends of the DNA double-strand break. DNA-PK (in complex with another 
protein Artemis) is large and bridges the gap between the two broken DNA ends so they are 
in close proximity. Artemis, when phosphorylated, can activate its endonuclease activity and 
deal with 5’ to 3’ overhangs and hairpins. More proteins are recruited to the site and the 
final ligation step of the two processed DNA ends is performed by the X-ray cross 
complementing 4 (XRCC4) - DNA ligase IV complex (Hall and Giacci, 2012). Mutations in this 
pathway can lead to syndromes like Ligase IV syndrome which is characterized by acute 
sensitivity to radiation and immunodeficiency (Chistiakov, 2010). The NHEJ pathway is 
illustrated in figure 1.1. 
 
Figure 1.1: Pathways of DNA double strand repair and some of the proteins involved. Left panel shows NHEJ where broken ends are 
joined directly. Right panel shows HR where homology of a sister chromatid is used to repair the break  (IARC, 2008). 
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DNA DSB that are not adequately repaired can result in chromosomal aberrations. 
Chromosomal aberrations can be in the form of acentric fragments, dicentrics, rings, 
translocations, inversions and deletions. These aberrations can result in genomic instability 
and subsequent carcinogenesis. If irradiation occurs before DNA synthesis, damage is 
replicated and occurs in both chromatids, resulting in chromosomal aberrations. If cells are 
irradiated after DNA synthesis, damage occurs in one chromatid arm only and are called 
chromatid aberrations. 
1.2 Radiosensitivity 
Clinical radiosensitivity is the display of adverse normal tissue side effects after exposure to 
ionising radiation for cancer treatment. In vitro chromosomal radiosensitivity is increased 
sensitivity of cells to the DNA-damaging effect of ionising radiation at the chromosome 
level. Increased in vitro chromosomal radiosensitivity has been shown in patients with 
different cancers, including breast, head and neck and prostate cancer (Parshad et al., 1983, 
Jones et al., 1995, Riches et al., 2001, Baeyens et al., 2002). This elevated chromosomal 
radiosensitivity is believed to be the result of inherited mutations in DNA repair genes that 
not only lead to increased chromosomal radiosensitivity in these patients but may also 
predispose them to cancer (Jeggo and Lavin, 2009). The first indication for a possible 
inherited basis for radiosensitivity came from patients with rare genetics syndromes such as 
Ataxia Telangiectasia and Nijmegen breakage syndrome (Jeggo and Lavin, 2009). These 
patients were shown to display both clinical and in vitro chromosomal radiosensitivity (Huo 
et al., 1994). Patients with these syndromes have germline mutations in genes involved in 
DNA damage repair and are also predisposed to many cancers. Studying chromosomal 
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radiosensitivity and its underlying mechanisms can further elucidate the link between 
inherited mutations in DNA damage repair genes and predisposition to cancer. 
1.3 Biomarkers of radiation-induced DNA damage 
Chromosomal damage induced by ionising radiation can be tested through a variety of 
assays. The traditional assay for radiation research is the analysis of dicentric chromosomes. 
While this technique is very sensitive (doses as low as 0.1 Gy can be detected) (Vaurijoux et 
al., 2009), one of its major disadvantages is it being time consuming and requiring highly 
skilled cytogeneticists. As alternatives, MN and γ-H2AX-foci have become two well-
established biomarkers of radiation-induced DNA damage. Recent automation of both these 
techniques has made them especially attractive because of increased speed and reduced 
subjectivity.  
1.3.1 The G0-Micronucleus assay 
The MN assay is a test that measures chromosomal aberrations, one of the major effects of 
ionising radiation. MN are small nuclei that form in the cytoplasm when whole 
chromosomes or chromosome fragments are not incorporated into the daughter nuclei 
subsequent to cell division (Norppa and Falck, 2003). In the MN assay, lymphocytes are 
irradiated in the G0 phase of the cell cycle. MN are the result of mis-repaired or non-
repaired DNA damage so they can be used as a biological marker to assess radiosensitivity.  
The MN assay is a well-established, robust assay in radiation research. It is performed on 
lymphocytes which can be easily obtained through venepuncture. After irradiation, cells are 
stimulated to divide with the addition of the mitogen, phytohaemagglutanin (PHA). To 
ensure that MN are scored in cells that have undergone one nuclear division, cytochalasin B 
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is added to block cytokinesis by preventing actin formation, resulting in binucleated cells 
(BN) (figure 1.2).   
 
Figure 1.2: Overview of the micronucleus assay. Lymphocytes which complete one nuclear division appear as BN (Baeyens, 2005) 
 
Introduction of image analysis systems using advanced computer algorithms have allowed 
the scoring of MN to become automated. The aim of automated MN scoring is faster 
detection of MN, improved accuracy and reduced need for highly trained personnel (Fenech 
et al., 2013). The Metafer 4 system of Metasystems (Altlussheim, Germany), an automated 
scoring platform for various cytogenetic tests, was first introduced in 2004 (Schunck et al., 
2004). The MNScore software module of the system identifies BN and MN based on a set of 
defined parameters called a classifier (figure 1.3). BN are detected by identifying two nuclei 
of similar size and shape. Detection of MN, in a defined area around the BN, is based on a 
series of morphology criteria. BN (with and without MN) are displayed in an image gallery at 
a 10x magnification. Studies have shown that staining of the cells with 4,6-diamidino-2-
phenydole (DAPI) results in the best fluorescence (Varga et al., 2004). MN in the image 
gallery can be checked manually by a scorer to correct for false positives and false negatives 
(figure 1.4). The Metafer has been widely documented in biodosimetry research studies and 
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in a few cancer research studies (Varga et al., 2005, Varga et al., 2006, Willems et al., 2010, 
Baeyens et al., 2011, Fenech et al., 2013, Thierens et al., 2014).  
 
Figure 1.3: Schematic representation of some of the parameters MNScore software uses to identify BN and MN  (Varga et al., 2004). 
 
 
 
Figure 1.4: The MNScore module of the Metafer 4 system showing BN with MN. In the red box, the bottom left corner indicates the MN 
score as determined by the system while the right bottom corner shows the MN count corrected by a scorer.  
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1.3.2 The γ-H2AX foci assay 
Nucleosomes, around which DNA is wrapped, are the basic building block of chromatin. 
They consist of octamers made of two copies of H2A, H2B, H3, H4 with the linker histone H1 
(Fernandez-Capetillo et al., 2004). H2AX is a variant of H2A. It varies from H2A as it has a 
highly-conserved COOH terminal tail. H2AX accounts for about 2-25% of the total H2A pool 
in mammalian cells (Rogakou et al., 1998). When a double strand break occurs, the serine 
139 within the COOH terminus of H2AX is phosphorylated by the protein ATM. 
Phosphorylation of this protein, referred to as γ-H2AX, rapidly spreads over an extensive 
region surrounding the double strand break leading to the formation of foci that can be 
detected microscopically with labeled phospho-specific antibodies (Rogakou et al., 1999). 
H2AX can also be phosphorylated in the absence of ATM by DNA-PK, resulting in similar 
levels of foci, however at a slightly slower rate (Stiff et al., 2004). In most cases the proteins 
work together in a redundant, overlapping manner to phosphorylate H2AX (Stiff et al., 
2004). 
The linear increase of γ-H2AX foci with increasing dose has made it a widely-used biomarker 
in radiobiology (Pilch et al., 2003, Beels et al., 2010). Foci are microscopically visible in G0 
lymphocytes which have low levels of background foci, making this a sensitive test 
(Rothkamm and Horn, 2009). Foci formation increases rapidly after exposure to radiation, 
reaches a maximum at 30 minutes to 1 hour later, and then decreases rapidly following the 
kinetics of double strand break repair (Rothkamm and Horn, 2009). Foci disappearance over 
time has been shown to follow double strand break rejoining and cells with impaired DNA 
damage repair pathways display reduced foci-loss (Rothkamm and Horn, 2009, van 
Oorschot et al., 2014). 
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Automated slide scanning and foci scoring on the Metafer 4 platform with the Metacyte 
software module of Metafer has been described in Vandersickel et al., (2010). This module 
recognises a cell nucleus based on the parameters of a classifier and captures it as a DAPI 
image at 40x magnification. In a second step, the filter is changed to a TRITC filter that 
detects fluorescent signals in a nucleus as a z-stack. Z-stacking allows a microscope to 
combine multiple images taken at different focus planes in a cell. DAPI-stained nuclei with 
fluorescent signals representing foci are displayed in the image gallery with an automated 
foci count that can be corrected by a scorer (figure 1.5). Automated counting of spots is 
based on 2 approaches: ‘direct spot count’ counts the number of fluorescent signals in a 
nucleus. However, as radiation dose increases, foci melt in to larger foci and ‘direct spot 
count’ will yield an underestimated count (Rothkamm and Horn, 2009). Therefore, the 
‘corrected foci count’ considers the 3D structure of the spots, and will result in a more 
accurate foci count (Vandersickel et al., 2010). While fully-automated foci scoring has been 
shown to be useful with the Metafer system (Vandersickel et al., 2010), manual scoring of 
foci allows for consideration of staining quality and can be more accurate at higher doses 
where foci are more complex (overlapping foci edges). It is also more accurate at lower 
doses where it is important to differentiate between true foci and background noise. 
Manual scoring of foci with the Metafer 4 system is the preferred method in current 
literature (Depuydt et al., 2013, Vandersickel et al., 2014).  
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Figure 1.5: The Metacyte module of the Metafer 4 system showing lymphocytes with γ-H2AX foci. The top right corners show the foci 
count as determined by the system while the bottom right corner indicates the foci count as determined by a scorer (red box). 
 
1.4 Cervical cancer 
1.4.1 General 
Cervical cancer is the most common cancer amongst women in Sub-Saharan Africa, with an 
age-standardised incidence rate of 34.8 per 105 females (IARC, 2012). It is also the leading 
cause of cancer-related deaths amongst women in this region (IARC, 2012). In South Africa, 
cervical cancer is the second cancer after breast cancer; however, it is the leading cancer 
amongst black South African women with a lifetime risk of 1/35 in compared to 1/82 in 
white women, according to the most updated national cancer registry available in South 
Africa (NCR, 2008). The high incidence of cervical cancer in South Africa is likely due to a 
combination of factors. These include lack of awareness of the disease and its causes, 
challenges in implementing regular screenings and limited access to HPV vaccinations, which 
were only recently introduced into the South African health care system (Anorlu, 2008, Sitas 
et al., 2008, Denny et al., 2013, DOHSA, 2014).  
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The female lower genital tract consists of three different compartments: endocervix, 
ectocervix and vagina (figure 1.6). The endocervix is covered by mucin-secreting simple 
columnar epithelium. The vagina and ectocervix are covered by stratified squamous 
epithelium, which acts as a physical barrier to pathogens. Squamous epithelial cells in the 
ectocervix grow as stratified epithelium. The basal layers divide as stem cells and after 
division, one of the daughter cells migrates upwards and undergoes terminal differentiation 
while the other daughter cell remains in the basal layer maintaining the self-renewing 
population (Narisawa-Saito 2007) (figure 1.7, figure 1.8). As the cells mature, they produce 
greater amounts of keratin and these squamous cells are often referred to as cervical 
keratinocytes. Invasive cervical cancers can be broadly divided into two groups according to 
their histology: these are non-keratinising, which are normally poorly differentiated, and 
keratinising, which are normally moderately to well differentiated. 
 
 
Figure 1.6: Anatomy of the female reproductive tract including endocervix, ectocervix and vagina (Bengtsson and Malm, 2014). 
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Figure 1.7: Structure of the ectocervix. CT = connective tissue, BM = basement membrane, L1 = basal cells, L2 = parabasal cells, L3 = 
intermediate cells, L4 = superficial cells, L5 = exfoliating cells (IARC, 2014). 
 
 
Figure 1.8: Different cells types found in the ectocervix (icytology, 2011) 
 
1.4.2 Cervical cancer and HPV 
Cervical cancer is caused by infection with oncogenic HPV (Walboomers et al., 1999, Bosch 
et al., 2002). Over 100 HPV have been classified based on sequences of the L1 gene of the 
virus which is highly conserved and codes for its capsid (figure 1.9) (de Villiers et al., 2004). 
The two main HPV genera are the alpha (α) and beta (β) genera which are further divided 
Superficial cells 
Intermediate cells 
Parabasal cells 
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into species (de Villiers et al., 2004). HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68, 73 and 82 are considered as high-risk for developing cervical cancer. HPV can be 
detected through a number of assays based on cell morphology (example: morphology of 
Pap smear cells); detection of HPV proteins (example: western blots or 
immunohistochemistry); detection of HPV genomes (example: polymerase chain reaction 
(PCR)) or detection of anti-HPV antibodies (example: Enzyme-linked immunosorbent assay 
(ELISA)) (Lina Villa and Denny, 2006). Local studies have shown that there are HPV-type 
distributions that are unique to the South African population (Moodley et al., 2010, De 
Vuyst et al., 2012, Denny et al., 2014).  
 
Figure 1.9: Phylogenetic tree of HPV subtypes(de Villiers et al., 2004). 
 
Infection with HPV occurs through microwounds in the transformation zone (border 
between endocervix and ectocervix) that allow the HPV virus to access the basal cells 
(Doorbar et al., 2012). As infected daughter cells migrate to the upper layers of epithelium, 
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viral genes are activated, resulting in high-level amplification of the viral genome (Narisawa-
Saito and Kiyono, 2007). In the outer layer of the epithelium, viral DNA is packaged into 
capsids and virions are released to reinitiate infection (figure 1.10). In most cases, viral 
infections are cleared by the body. However, if the virus integrates into the host genome, 
carcinogenesis can occur. Upon integration, the viral gene E2 becomes deactivated which 
results in the expression of viral genes E6 and E7 (Narisawa-Saito and Kiyono, 2007). 
Expression of E6 and E7 interfere with host p53 and pRb, two important proteins in tumour 
suppression and cell cycle regulation.  E6 forms a stable complex with a ubiquitin-protein 
ligase called E6-AP. This complex binds to p53 and induces multi-ubiquitination. The 
ubiquitinated p53 is then recognized by a large multi-subunit protease complex, called the 
26S proteasome, which degrades it into small peptides (Scheffner, 1998). Degradation of 
pRb by E7 is also mediated by the ubiquitin-proteasome pathway (Boyer et al., 1996).  
 
 
Figure 1.10: Life cycle of  HPV in the squamous cells of the ectocervix (Nobelprize.org, 2008). 
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The reason why some women infected by HPV develop cervical cancer while others don’t is 
still unknown (Woodman et al., 2007, Jaisamrarn et al., 2013). Heritability studies have 
shown that there is a genetic link to cervical cancer susceptibility and that the disease shows 
familial clustering (Magnusson et al., 1999, Magnusson et al., 2000, Zelmanowicz Ade et al., 
2005). While many heritability studies on cervical cancer have focused on genes involved in 
immune response (Chen et al., 2013, Jiang et al., 2013, Chen et al., 2014), recent reports 
have shown an association between cervical cancer and genes involved in DNA damage 
repair. These include genes such as APE1, XRCC2, XRCC3, ERCC1, ERCC2, ERCC4, ATM 
(Oliveira et al., 2012, Bajpai et al., 2013, Perez et al., 2013, Wang et al., 2013).  
1.4.3 Cervical cancer and HIV 
By mid-2014, there were 5.5 million people in South Africa infected with HIV (STATSSA, 
2014). HIV, HPV and cervical cancer are epidemiologically associated and in 1993 Invasive 
cervical carcinoma was classified as an AIDS-defining illness by the United States Centers for 
Disease Control and Prevention (CDC, 1993). Studies have shown that infection with HPV is 
higher in HIV-positive than in HIV-negative women, even after taking into account potential 
confounding factors such as age and sexual behaviour (Sitas et al., 2008, Adler, 2010). 
Chances of HPV infection increase with decreasing CD4 cell count (Firnhaber et al., 2010, 
Mbulawa et al., 2010). HIV-positive women have a higher incidence of cervical lesions 
compared to HIV-negative women (Denslow et al., 2014). In 2012, there were more than 2 
million South Africans on Antiretroviral treatment (ARV) (UNAIDS, 2013). Although potent 
ARV clearly benefit the patient’s immunity in terms of increasing CD4 counts, this does not 
seem sufficient to resolve high-risk HPV persistence and the role of ARV in cervical cancer 
incidence remains unclear (De Vuyst et al., 2008, Adler, 2010, Denslow et al., 2014).  
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1.4.4 Cervical cancer and chromosomal radiosensitivity 
The in vitro chromosomal radiosensitivity of lymphocytes of cervical cancer patients has 
been investigated using a variety of cytogenetic assays, however results have been unclear 
(Baria et al., 2001, Ban et al., 2004, Bozsakyova et al., 2005, Gabelova et al., 2008). 
Conflicting studies related to treatment of cervical cancer indicate that the MN assay has no 
value in predicting clinical radiosensitivity or clinical outcome (Slonina et al., 2000, Gabelova 
et al., 2008, Slonina et al., 2008), while others show the MN assay to have predictive value 
(Widel et al., 1999, Widel et al., 2001, Widel et al., 2003). The HPV virus has been shown to 
potentially play a role in radiosensitivity of cervical cancer tumours (Vozenin et al., 2010). 
Tumours positive for the α7 HPV subtypes (HPV 18, 39, 45, 68, 70) show reduced 
radioresponsiveness and a worse prognosis than α9 HPV subtypes (HPV 16, 31, 33, 35, 52, 
58) after radiotherapy treatment (Hall et al., 2013). Patients with HPV-positive squamous 
cell carcinomas of the head and neck (HNSCC) display improved survival outcome to their 
HPV-negative HNSCC counterparts after radiotherapy (Kimple et al., 2013). This has been 
confirmed by studies showing increased in vitro radiosensitivity of HPV-positive HNSCC cell 
lines compared to HPV-negative ones (Rieckmann et al., 2013). Despite the high incidence of 
cervical cancer in South Africa, and the extensive use of radiotherapy to treat it, there are 
no data on the chromosomal radiosensitivity of South African cervical cancer patients.  
Due to the high rate of HIV in South Africa and its association with cervical cancer, it is likely 
that a significant proportion of cervical cancer patients receiving radiotherapy as part of 
their treatment will be HIV-positive. Baeyens et al., (2010) showed that individuals infected 
with HIV are more chromosomally radiosensitive than uninfected controls, however this has 
not been confirmed on a cancer population. 
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1.5 Breast Cancer 
1.5.1 General 
Breast cancer is the leading cancer amongst South African women, with a lifetime risk of 1 in 
34 (NCR, 2008). South Africa is a country consisting of citizens from diverse ethnic groups. 
These include: black/African (80.2%), white/Caucasian (8.5%), mixed/coloured (8.9%) and 
Indian/Asian (2.4%) (STATSSA, 2014). The lifetime risk of breast cancer differs according to 
ethnicity with 1/52 in black women, 1/18 in white women, 1/22 in coloured women and 
1/19 in Indian women (NCR, 2008). It is well known that African populations have more 
genetic diversity than other populations. While the lifetime risk of developing the disease is 
lower in African women than in white, coloured and Indian women, it is rising due to 
increased life expectancies and urbanisation which leads to lifestyle changes that elevate 
exposure to known risk factors for breast cancer such as change in diet, delayed and 
decreased parity, reduction in breast feeding and exercise (Porter, 2008, Porter, 2009, Knaul 
et al., 2012). The mortality rate of existing South African breast cancer patients is high, 
owing to limited access to hospitals in rural areas, diagnosis at more advanced stages, lack 
of awareness, poor socio-economic status, and limited screening of breast cancer markers 
(Igene, 2008).  
Breast cancer can be sporadic or familial. Mutations in highly penetrant genes such as 
BRCA1/2, which normally occur in familial cases, only account for about 5% of all breast 
cancer patients (Nathanson et al., 2001). A substantial amount of patients may be 
predisposed to breast cancer through mutations in low penetrance genes. Genes other than 
BRCA1/2 involved in DNA damage repair, for example, Partner and localizer of BRCA2 
(PALB2) and Checkpoint kinase 2 (CHEK2), have shown to be good candidates for breast 
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cancer predisposition (Lina Villa and Denny, 2006, Bau et al., 2007, Smith et al., 2008, 
Willems et al., 2008, Ricks-Santi et al., 2011, Vral et al., 2011).  
The two main categories of breast cancer are Ductal and Lobular, depending on where in 
the breast the abnormal cells originate (figure 1.11). Breast cancer is considered in situ 
before abnormal cells invade surrounding tissue and invasive once cancerous cells infiltrate 
into other parts of the breast. Hormone receptor status (estrogen receptor (ER), 
progesterone receptor (PR)), Human epidermal growth factor receptor 2 (HER2) status, 
tumour grade and stage are important features determining treatment and prognosis in 
breast cancer. 
 
Figure 1.11: Anatomy of the breast.(MUSCHealth, 2014) 
 
1.5.2 Breast cancer and chromosomal radiosensitivity 
Many studies, using a range of cytogenetic assays, have shown unequivocally that breast 
cancer patients are more sensitive to ionising radiation than healthy individuals. Until now, 
these studies have only been performed on European, Asian, American and African- 
American populations (Scott et al., 1994, Terzoudi et al., 2000, Riches et al., 2001, Baeyens 
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et al., 2002, Varga et al., 2006, Poggioli et al., 2010, Ryabchenko et al., 2012, Djuzenova et 
al., 2013). Chromosomal radiosensitivity has never been investigated in a South African 
breast cancer cohort. 
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2 Aims and rationale 
The overall aim of the study was to investigate the chromosomal radiosensitivity of South 
African cervical and breast cancer patients. Investigating the chromosomal radiosensitivity 
of these patients can lead to insights on both predisposition to the diseases, as well as on 
the radiotherapy treatment of these patients. Two tests were used to measure different 
biological endpoints, induction of DSB after radiation (γ-H2AX foci assay) and chromosomal 
damage after radiation (MN assay).  
2.1 Cervical cancer research objectives 
1. Investigate the chromosomal radiosensitivity, using the MN assay with the Metafer4 
platform, of South African cervical cancer patients in a case-control study design. 
Concurrently evaluate the quality of this assay on these patients and validate 
different scoring methods available for the MN assay with the Metafer 4 platform. 
Recent automation of the MN assay with the Metafer 4 of Metasystems has made this an 
attractive assay for biodosimetry and radiosensitivity studies. Two scoring methods have 
previously been described with this platform. The ‘fully-automated’ scoring method 
(Willems et al., 2010) and the ‘semi-automated’ scoring method (Baeyens et al., 2011, 
Bolognesi et al., 2011, Thierens et al., 2014). In this study, a second ‘semi-automated’ 
scoring method was introduced as an extra validation. The three scoring methods were 
compared on the lymphocytes of cervical cancer patients and healthy controls.  To evaluate 
the quality of this assay on these patients, rate of success of cultures was determined and 
the average nuclear division index (NDI) was calculated for the different groups. 
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2. Compare the MN values of HIV-negative cervical cancer patients, HIV-positive 
cervical cancer patients and healthy controls.  
Comparing the chromosomal radiosensitivity of HIV-negative patients to controls 
investigates a potential link between chromosomal radiosensitivity and predisposition to 
cervical cancer. Baeyens et al. (2010) showed HIV-positive individuals to have higher 
chromosomal radiosensitivity compared to HIV-negative individuals. This has never been 
confirmed on a cancer cohort. The epidemiological link between cervical cancer and HIV in 
South Africa means that many of these patients seeking treatment, often radiotherapy, will 
be HIV-positive. To determine if there is an effect of HIV on the chromosomal 
radiosensitivity of the cervical cancer patients, the group of cervical cancer patients was 
divided into HIV-positive and HIV-negative patients and the MN values of these were 
compared to healthy controls.  
3. Investigate if there is any correlation between chromosomal radiosensitivity of South 
African cervical cancer patients and clinical parameters of disease stage and 
histology. Also investigate if there is any correlation between chromosomal 
radiosensitivity and age of onset of the disease. 
Patients were divided into groups according to these parameters and age and MN values 
were compared between the subgroups. 
4. Perform the γ-H2AX foci assay on the lymphocytes of HIV-negative cervical cancer 
patients and healthy controls.  
This assay looks at a different biological end-point to the MN assay. It gives information on 
DNA double strand break induction after exposure to radiation and residual DSB after 
 24 
 
repair, while the MN assay measures chromosomal damage resulting from mis/non-
repaired DSB after exposure to radiation. This assay does not require dividing cells, which 
was seen to be challenge with the MN assay. γ-H2AX foci were measured 30 mins and 24 hrs 
after exposure to radiation.  To measure the amount of repair undergone by each sample, a 
‘repair factor’ was calculated.  
5. Compare repair factors with MN values in lymphocytes of HIV-negative cervical 
cancer patients and healthy controls. 
The MN assay was performed on the same set of samples as above. Since the two assays 
measure different endpoints, foci and MN values cannot be directly compared, however the 
repair factors can be compared to MN values as they both give information on residual 
damage. 
6. Develop a MN assay that can be performed on cervical biopsy tumour cells and 
exfoliated cervical cells of cervical cancer patients and compare MN values in 
lymphocytes, cervical tumour biopsy cells and exfoliated cervical cells to determine if 
there is concordance in the number of MN and chromosomal radiosensitivity across 
the three cell types.  
Cervical cancer tumour biopsies and exfoliated cervical cells can be obtained with fairly non-
invasive procedures. This gives the unique opportunity to obtain tissue that will be directly 
affected during radiation treatment. Performing the MN assay on these cells could lead to a 
predictive radiosensitivity screening test to determine how normal and tumour tissue of 
cervical cancer patients may respond clinically to radiotherapy. 
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7. Develop and optimise an in-house PCR that can be used to genotype HPV. Determine 
the HPV subtypes in DNA extracted from patient tumour biopsies and correlate this 
with MN values of lymphocytes.  
HPV has been shown to play a role in radiosensitivity. Cervical cancer risk may be a result of 
interaction between the HPV and host genes involved in DNA damage repair. Chromosomal 
radiosensitivity may indicate susceptibility to certain HPV subtypes.  
2.2 Breast cancer research objectives 
1. Perform the MN assay on lymphocytes of South African breast cancer patients and 
investigate the differences in chromosomal radiosensitivity of breast cancer patients 
from different ethnic groups. 
European and American studies have shown that breast cancer patients are more 
radiosensitive than controls at the chromosome level (Scott et al., 1994, Terzoudi et al., 
2000, Riches et al., 2001, Baeyens et al., 2002, Varga et al., 2006, Poggioli et al., 2010, 
Ryabchenko et al., 2012, Djuzenova et al., 2013). This has never been performed on a 
population living in South Africa. South Africa has a diverse population with women from 
different ethnic backgrounds including African, European, Indian and Mixed-race. This 
unique setting allows the chromosomal radiosensitivity of different ethnic groups to be 
measured and compared. 
2. Investigate if there is any correlation between chromosomal radiosensitivity of South 
African breast cancer patients and clinical parameters and age of onset of the 
disease. 
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Patients were divided into groups, positive or negative for hormone receptors estrogen and 
progesterone and the HER2 receptor. They were also divided into groups based on tumour 
size, stage, and histology. MN values between subgroups were compared. The influence of 
age was also investigated. 
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3 Materials and Methods 
3.1 Study populations 
3.1.1 Cervical cancer 
Cervical cancer patients (n = 147) were recruited from Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH), a public hospital in Johannesburg, where they were undergoing 
curative hysterectomies or starting their treatment. Both HIV-positive and HIV-negative 
patients were recruited. Only patients with squamous cell carcinoma were included, as 
approximately 80-90% of cervical carcinomas amongst South African women are of this 
histological subtype (Lomalisa et al., 2000, Denny et al., 2014). Exclusion criteria included: 1) 
adenocarcinomas; 2) recent blood transfusion; 3) previous cancers; 4) prior chemotherapy 
or radiotherapy and 5) CD4 counts below 300 cells/mm2 in HIV-positive patients (not 
optimal for lymphocyte culturing according to Baeyens et al., (2010)). Heparin and Ethylene-
diamine-tetra-acetate (EDTA) blood tubes were collected from all patients. Cervical smears 
and biopsies (fresh tissue or formalin-fixed paraffin-embedded (FFPE)) were also collected. 
FFPE were obtained from the Division of Anatomical Pathology, School of Pathology, 
University of Witwatersrand. For patients undergoing hysterectomies, a tumour and an 
adjacent piece of healthy tissue was collected to optimise cell culturing techniques.  
Patient clinical and biographical information was obtained through questionnaires 
(Appendix B) and hospital files. Clinical information obtained from patient files included: 1) 
tumour histology type; 2) stage of cancer; 3) HIV status, CD4 count and if patient was on 
ARV. Biographical information obtained from questionnaires included 1) ethnicity and 
birthplace; 2) income; 3) education; 4) information on smoking and other illnesses. All 
donors signed informed consent and ethical approval for the study was obtained through 
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the Human Research Ethics Committee, University of Witwatersrand, Johannesburg, South 
Africa (M110230) (Appendix B). 
3.1.2 Breast cancer 
Heparinised blood samples were collected from breast cancer patients (n = 137) recruited 
from both CMJAH and University of the Witwatersrand Donald Gordon Medical Centre, a 
private hospital in Johannesburg. Exclusion criteria included: 1) previous cancers; 2) prior 
chemotherapy or radiotherapy. Patient clinical and biographical information was obtained 
through questionnaires (Appendix B) and hospital files. Clinical information obtained from 
patient files included: 1) tumour histology type; 2) stage of cancer; 3) grade of cancer; 4) 
size of tumour; 5) Estrogen, progesterone and HER2 receptor status and 6) HIV status and 
CD4 count. The same biographical information was obtained in the questionnaires as in the 
cervical study, except an extra question on status of menopause was included. All donors 
signed informed consent and ethical approval for the study was obtained through the 
Human Research Ethics Committee, University of Witwatersrand, Johannesburg, South 
Africa (M110248) (Appendix B). 
3.1.3 Healthy controls 
Heparinised blood samples from healthy controls (n = 91) were also collected. These were 
female students and staff members at CMJAH. The age and ethnicities of these controls 
were matched to patients. Twenty six exfoliated smear samples were also collected from 
healthy women attending a colposcopy clinic at CMJAH to optimise cell culturing 
techniques. 
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3.2 Micronucleus assay on peripheral blood lymphocytes 
The MN assay was performed to investigate the in vitro chromosomal radiosensitivity of 
both South African cervical and breast cancer patients. MN values were also used to 
determine if there is an influence of clinical parameters and age on chromosomal 
radiosensitivity. 
3.2.1 Irradiation and blood cultures 
Chromosomal radiosensitivity was measured by irradiating blood in vitro with doses of 2 Gy 
and 4 Gy. A dose of 2 Gy was used as this is the fractionated-dose given during conventional 
radiotherapy treatment. A dose of 4 Gy was also administered to increase the sensitivity of 
the test. A 0 Gy dose was included as a sham-irradiated control. Radiations were done in the 
Radiation Oncology Unit at CMJAH. Cultures were stimulated into division immediately after 
irradiation with PHA and incubated at 37°C. Cytochalasin B was added after 23 hrs to block 
cytokinesis. After 70 hrs cells were harvested with hypotonic shock and fixed in 
methanol:acetic acid. Duplicate slides were made and stained with vectashield containing 
DAPI (4,6-diamidino-2-phenylindole; Vector Laboratories, Burlingame, USA). Two co-
cultures were set up for each dose, accounting for experimental variability. See Appendix C 
for a detailed protocol of the MN assay.  
3.2.2 Slide scanning and scoring 
Slides were scanned on the Metafer 4 platform connected to a motorised Zeiss AxioImager 
M1 microscope. The settings for the classifier were based on Willems et al. (2010). Three 
different scoring methods (involving varying degrees of visual validation of automated 
scores) were compared and validated. The first was the ‘fully-automated’ scoring method in 
which MN counts are based directly on those obtained by the MNScore module (Willems et 
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al., 2010). The second is a ‘semi-automated’ scoring method which has been validated and 
published elsewhere (Baeyens et al., 2011, Bolognesi et al., 2011, Thierens et al., 2014). In 
this method, referred to here as ‘semi-automated A’, only false positive MN are corrected 
by the scorer. For this study, a third scoring method, referred to as ‘semi-automated B’ was 
introduced as an extra validation. In this method, every BN cell is checked by the scorer and 
both false positive and false negative MN are corrected. Using cervical cancer samples and 
healthy controls as the cohort, ‘fully-automated’, ‘semi-automated A’ and ‘semi-automated 
B’ MN scores were obtained. For the breast cancer patients, results were based on the 
‘semi-automated B’ MN scores only. Radiation-induced MN values were obtained by 
subtracting background MN values for each dose point. Any data points with less than 500 
BN per dose were excluded. In general, between 500-2000 BN were scored. All results were 
normalised to a MN frequency in 1000 BN.  
3.2.3 Nuclear division index 
To assess the proliferative status of lymphocytes of cervical cancer patients, the NDI was 
calculated on a sub-set of HIV-negative, HIV-positive cervical cancer patients and healthy 
controls.  The formula was NDI = (N1+2N2+3N3+4N4)/Ntotal, where N1-N4 is the number of 
cells with 1-4 nuclei and Ntotal is the total number of cells scored (Ntotal = 500) (Fenech, 
2007). For this, slides from the MN assay were stained with acridine orange (Appendix D) 
(Sigma-Aldrich, St Louis, MO, USA). 
3.3 γ-H2AX Foci assay on peripheral blood lymphocytes 
The γ-H2AX assay was performed on the lymphocytes of HIV-negative cervical cancer 
patients and healthy controls at 30 mins after exposure to radiation, to allow for maximal 
foci formation (Rothkamm and Horn, 2009), and 24 hrs after exposure, the time widely used 
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in γ-H2AX foci studies to investigate DNA damage repair (Beels et al., 2010, Djuzenova et al., 
2013, van Oorschot et al., 2014, Vandersickel et al., 2014).  
3.3.1 Lymphocyte isolation 
Peripheral blood was collected in tubes with EDTA which has good anti-coagulation 
properties for separation of cells. Lymphocytes were isolated from whole blood using low 
density gradient centrifugation. See Appendix C for a detailed protocol. 
3.3.2 Irradiation and cultures 
For the γ-H2AX foci assay, isolated lymphocytes were irradiated with the same set-up as for 
the MN assay. Since doses of 2 Gy and 4 Gy, used in the MN assay, could result in foci per 
cell too numerous to be accurately counted by eye (Scherthan et al., 2008, Rothkamm et al., 
2013), lymphocytes were irradiated with 0.5 Gy and 1 Gy doses. A non-irradiated control of 
0 Gy was included. For each dose point, two co-cultures were set-up. Lymphocytes were 
placed in a waterbath for 30 mins at 37°C immediately after irradiation. Thereafter, cells 
were placed on ice for 20 mins to arrest DNA damage repair. After time on ice, 250 µl cell 
suspensions were spun onto Poly-L-lysine coated slides (Thermo Scientific, Massachusetts, 
USA) at 500 revolutions per minute (rpm) for 5 mins in a Cytospin, which facilitates the 
attachment of cells to the slides. Cells were fixed onto slides by placing them in 3% 
Paraformaldehyde (PFA) (Merck, Darmstadt, Germany) (Appendix D) for 15 mins at room 
temperature (RT), followed by 0.5% PFA (Appendix D) overnight at 4°C. Tubes with 
remaining cells were transferred from the waterbath to a 37°C pre-gassed (5%CO2/95% air) 
incubator and the procedure was repeated at 24 hrs. 
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3.3.3 γ-H2AX immunostaining 
After overnight fixation, slides were immunostained with primary antibody anti-phospho-
histone H2AX (Biolegend, San Diego, USA) followed by secondary antibody Rabbit-anti-
mouse tetramethyl rhodamine isothiocyanate (RAM-TRITC) (Dako, Glostrup, Denmark) 
which results in a fluorescent signal that can be viewed microscopically. See Appendix C for 
a detailed protocol.  
3.3.4 Slide scanning and scoring 
Slides were scanned on the Metafer 4 platform connected to a motorized Zeiss AxioImager 
M1 microscope using the Metacyte module. The settings for the classifier were based on 
Vandersickel et al. (2010), except 3 focal planes instead of the 10 were used in the z-stack. 
This reduces the time taken to scan a slide and still yields reliable foci scores. Quality of 
immunostaining was checked across slides before scoring. Since manual scoring is more 
accurate than automated scoring for both high (foci overlap) and low (background noise) 
radiation doses, only manual foci scorings were used for the analysis. Foci in 100 cells per 
condition were counted to give a result of the mean number of foci/cell. Cells with 
apoptotic morphologies or bright nuclei (complete coverage by immunostain) were 
excluded from the analysis. 
3.4 Micronucleus assay on cervical biopsy tumour cells and exfoliated cervical cells 
In order to perform the MN assay on these cells, in vitro cultures needed to be established 
as the MN assay requires dividing cells. Immunohistochemistry (IHC) on these cultures with 
Anti-pan Cytokeratin Antibody AE1+AE3 from abcam® (Cambridge, England, United 
Kingdom) ensured that the correct cells, cervical keratinocytes (cervical epithelial cells 
transformed by HPV), were cultured. 
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3.4.1 Tumour biopsy cultures 
A protocol for culturing tumour biopsies was established in-house by combining and 
adapting the protocols of Widel et al., (1999); Brink et al., (2002); Heymer et al., (2009); 
Darroudi et al., (2010) and Freshney, (2010). Fresh biopsies were placed in collection 
medium (Freshney, 2010) (Appendix D) at 4°C until processing (<4 hrs). Many biopsies, 
especially those of late-stage disease, consisted of disintegrating brownish tissue material, 
indicating severely necrotic tissue. These samples were not suitable to be cultured. The use 
of fine needle aspirates from tumours was attempted to obtain single-cell suspensions, but 
this yielded insufficient cells for culturing. Viable samples were minced with a sterile scalpel 
before digestion. Various steps for optimisation of digestion were tested (table 3.1).  
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Table 3.1: Optimisation of tumour digestion. 
Digestion Enzyme Manufacturer Reference Concentration Digestion conditions Outcome 
Collagenase/Dispase Roche 
Diagnostics 
(Widel et al., 1999) 
(Darroudi et al., 2010) 
 
1 mg/ml 37°C for ±1 hr, according to manufacturer 
instructions 
Optimisations:  
Increased digestion time up to 24 hrs and 48 
hrs.  
1X and 2X concentrations. 
Inadequate digestion 
in all conditions 
Collagenase Sigma-Aldrich Digestion protocol of 
intestinal tumours 
from colleagues in 
another department. 
1 mg/ml 37°C for ±1 hr Inadequate digestion 
Liberase Research 
Grade Purified 
Enzyme Blend 
Roche 
Diagnostics 
(Heymer et al., 2009) 0.12 mg/ml 37°C for ±1 hr, according to manufacturer 
instructions 
Optimisations:  
Increase digestion time to ±12 hrs.  
Adequate digestion  
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Once biopsies had been adequately digested, they were strained through a 70 µm Falcon 
mesh strainer (BD Biosciences, New Jersey, USA) and loose cells were washed in DMEM/F12 
(BioWhittaker, Walkersville, USA) with 10% Foetal Bovine Serum (FBS) (Gibco-Invitrogen, 
New York, USA) to halt the activity of digestion enzymes. Cell viability was determined with 
trypan blue (Sigma-Aldrich) staining and cells were counted with a haemocytometer. To 
allow for attachment, cells were seeded in 24 well plates (Greiner Bio-One, Monroe, North 
Carolina, USA) at a density 1 X 106 cells/ml with 0.8 ml culture-initiation medium (Brink et al, 
2002 with modifications) (Appendix D). Obtaining this density of viable cells was not 
possible in most cases, so all cells were seeded and cell concentration was monitored and 
adjusted by visual checking under an inverted light microscope (Light Microscope Prima 
Vert, Zeiss Gottingen, Germany). Table 3.2 shows the steps taken to improve attachment of 
keratinocytes. 
Table 3.2: Optimisation of cell attachment.  
Optimisation Effect 
Increase time in culture-initiation medium from 24 hrs to 48 hrs No attachment 
CellBind® (Corning) plates treated with oxygen to be more 
hydrophilic for optimal cell attachment 
Average attachment 
Treat plates with Poly-L-lysine (Appendix D), a synthetic amino 
acid that is positively charged and aids attachment of cells to 
plastic 
Good attachment 
 
After 48 hrs, culture-initiating medium was removed and replaced with specialised 
Keratinocyte Growth Medium (KGM) (Lonza, Basel, Switzerland). This is a serum-free 
medium that is supplemented with Singlequots (Lonza) containing growth factors, insulin, 
hydrocortisone, antibiotics, cytokines and other supplements such as bovine pituitary 
extract to stimulate keratinocyte division. Despite attachment, sufficient growth of cells did 
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not take place in cultures and confluence was not reached in any samples.  Literature 
suggests that extracellular calcium concentrations exert effects on the morphology, 
proliferation and differentiation of keratinocytes in serum-free medium.  Therefore, culture 
of cervical tissue was attempted in Keratinocyte growth medium supplemented with 
calcium to 0.4 mM (Fichorova et al., 1997).  
3.4.2 Exfoliated cervical cell cultures 
Exfoliated cervical cells were collected from healthy women attending a colposcopy clinic at 
CMJAH to optimise cell culture methods. Exfoliated cervical cells usually contained many red 
blood cells, which could hinder keratinocyte attachment. Therefore, a lysis step was 
implemented.  Cells were resuspended in erythrocyte lysis buffer (Appendix D) for 5 mins at 
RT, washed in complete medium (Appendix D) twice and counted with a haemocytometer. 
As cervical smears consist mainly of superficial keratinocytes cells that become very 
flattened as they differentiate, transparent, viable ones were difficult to observe with 
trypan blue staining, therefore cells were stained with acridine orange instead. This 
fluorescent stain enhanced visualisation of keratinocytes under the microscope and 
improved viability checking. Many samples were discarded at this stage due to fungal 
infection and/or dead cells. In samples with healthy cells (good morphology), cells were 
planted in wells coated with Poly-L-lysine (Appendix D) in culture-initiation medium 
(Appendix D) to allow for attachment (as above). Once attachment occurred medium was 
replaced with KGM (Lonza) supplemented with calcium to 0.4 mM. 
3.4.3 Immunohistochemistry to characterise cultured cells 
Immunohistochemistry with Anti-pan Cytokeratin Antibody AE1+AE3 from abcam® was used 
to characterise keratinocytes in culture. Primary mouse monoclonal antibodies AE1 and AE3 
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bind to cytokeratin antigens that are specific markers of epithelial cell differentiation. The 
secondary antibody was biotinylated rabbit-anti-mouse antibody (Dako, Glostrup, Denmark) 
which can be visualised microscopically by adding labelled strepavidin (Dako) which has a 
strong affinity for biotin. The antibody was tested for specificity on five cervical biopsies (3 
normal ectocervix and 2 tumour biopsies). See Appendix C for a detailed protocol. 
3.5 HPV genotyping 
HPV genotyping was done on the DNA from biopsies of cervical cancer patients.  
3.5.1 DNA extraction 
DNA was extracted from fresh biopsy tissue and FFPE tissue. Extraction of DNA from fresh 
biopsies was done with the QIAamp DNA Mini Kit (Qiagen, Venlo, Netherlands). For FFPE, 
DNA was extracted using the phenol-chloroform method. See Appendix C for detailed 
protocols. DNA concentrations were determined using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, Massachusetts, USA). Extracted DNA was stored at -
20°C until HPV genotyping. 
3.5.2 Multiplex PCR 
A multiplex HPV genotyping PCR was established in-house based on the methods of 
Nishiwaki et al., (2008). The protocol allows for the simultaneous detection of multiple HPV 
types in a single-tube reaction using genotype-specific primers. The HPV types included 16, 
58, 52, 51, 56, 31, 18, 39, 66, 59, 6, 33, 35, 45, and 11. These primer sets included HPV types 
16, 18, 35, 45, common sub-types in the tumours of South African cervical cancer patients 
(De Vuyst et al., 2012, Denny et al., 2014). PCR products were separated by 2% agarose gel 
(Appendix D) electrophoresis and HPV type-specific amplicons were visually identified based 
on fragment size. Gels were stained with Gelred (Biotium, California, USA) and run at 80-100 
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Volts for 40 mins. See Appendix C for detailed protocol. The PCR was optimised with the 
following steps: 
1. PCR primers (sequences from Nishiwaki et al. 2008) were obtained from Integrated 
DNA technology (Leuven, Belgium). 
2. Positive and negative controls typed by a routine laboratory with the Abbott 
RealTime High Risk HPV assay, for clinical purposes, were obtained. This DNA was 
typed according to HPV 16 positive, HPV 18 positive or ‘other’ (High-risk HPV 
subtypes other than HPV 16 or HPV 18).  
3. PCR consumables were from a Qiagen Multiplex PCR kit.  
Component Volume/reaction Final concentration 
2X Qiagen Multiplex PCR Mastermix 25 µl 1X 
10X primer mix (primers at 2 µM) 5 µl 0.2 µM 
DNA variable <1 µg 
H2O variable  
Total Volume 50 µl  
 
4. PCR cycling conditions were initially optimised on controls amplifying the internal 
control (IC) only. Aminolevulinate deltasynthase, a commonly-used housekeeping 
gene, was the internal control and was included to test integrity of template DNA.  
PCR conditions were: 
Step Time T°  
Initial activation step 15 min 95°C  
Denaturation 30s 94°C Number of 
cycles = 40 
Annealing 90s 60°C 
Extension 90s 72°C 
Final extension 10 min 72°C  
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5. Once there was amplification of the internal control, the PCR was tested on positive 
controls for HPV 16 (primers for HPV 16 and the IC at 2 µM each). The number of 
cycles in the PCR was reduced to 35 cycles which resulted in ‘neater’ bands. The final 
PCR cycling conditions were as follows: 
Step Time T°  
Initial activation step 15 min 95°C  
Denaturation 30s 94°C Number of 
cycles = 35 
Annealing 90s 60°C 
Extension 90s 72°C 
Final extension 10 min 72°C  
 
6. The PCR was then tested on positive controls for HPV 18. The cycling conditions used 
for HPV 16 (table above) were maintained. The primer mix of HPV 18 was optimized 
to concentrations of HPV 18 at 1 µM and IC at 3 µM.  
7. When typing samples positive for HPV 18 and other HPV subtypes, the best results 
were obtained by reducing the concentration of HPV 18 primers to 0.5 µM. The same 
applied to HPV 16. 
8. A screening of the DNA samples, typed with the Abbott kit revealed positive controls 
for all HPV subtypes in the protocol except 35, 56 and 58. Positive controls for 35, 56 
and 58 were obtained from the WHO HPV LabNet HPV DNA Typing Proficiency Study 
(Eklund et al., 2014). New primers were required for HPV 58 which were based on 
those of Romero-Pastrana, (2012). 
9. The amount of the PCR consumables were halved to make the test more cost-
effective. 
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10. To do multiple typings in one tube, the primer sets were split into 4 mixes according 
to band size for easier detection on a gel. These 4 mixes are shown below from 
smallest gel band in base pairs (bp) to largest. 
Mix 1       
HPV subtype IC 59 45 16 11 
 Size (bp) 99 169 205 397 472 
 Primer concentration 
µM (10X primer mix)  3 2 0.5 0.5 3 
 
       Mix 2      
 HPV subtype IC 18 39 6 51 52 
Size (bp) 99 187 229 263 299 517 
Primer concentration 
µM (10X primer mix)  3 0.5 2 0.5 2 0.5 
       Mix 3      
 HPV subtype IC 66 56 58 
  Size (bp) 99 277 330 414 
  Primer concentration 
µM (10X primer mix)  2 3 3 3  
 
       Mix 4      
 HPV subtype IC 33 31 35 
  Size (bp) 99 139 360 434 
  Primer concentration 
µM (10X primer mix)  2 2 2 2 
   
11. DNA from cervical patients was typed with the final 4 primer mixes. Cycling 
condition remained the same as in step 5. 
 
3.6 Statistical analysis 
Statistical analysis was performed with SPSS (IBM, version 22) and Graphpad Prism 6. 
Differences between means of MN counts in cervical, breast patients and controls were 
tested for significance with the Mann-Whitney U test. Differences in MN values between 
groups according to clinical parameters and age were also tested for significance with the 
Mann-Whitney U test. Differences in NDI scores between groups were also tested with the 
 41 
 
Mann-Whitney U test. This statistical test was used as it is a non-parametric, distribution-
free test that is suitable to compare groups with small sizes where no underlying 
distribution can be assumed. Correlations were tested with Pearson’s correlation 
coefficient. Differences in means of age and tumour size in breast cancer patients were 
tested using ANOVA. Differences in characteristics of breast cancer patients were tested for 
differences with the Chi-squared test. 
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4 Results 
4.1 Cervical cancer patients 
4.1.1 Study population 
A total of 147 cervical cancer patients were recruited during the study. Table 4.1 shows the 
biographical and disease characteristics of the study population. The majority of patients 
were black (91%). Only 54% could be considered to be ‘educated’ (high school and tertiary 
school). Most of the patients were of low-income status with only 3% in an income bracket 
above R5000/month. The majority (47%) of patients presented with late-stage disease. 
Forty-two percent of the patients were HIV-positive. The average age of patients was 47 
(range = 27-79). The average age of the HIV-positive group was 42 (range = 27-60), 
compared to 52 (range = 29-79) average age of the HIV-negative group. The average CD4 
count in the HIV-positive group was 493 cells/mm3. Since CD4 counts are not normally 
measured in HIV-negative cervical cancer patients in the clinical setting, these were not 
available for this group of patients. 
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Table 4.1: Characteristics of cervical cancer patients. 
Race n % 
Black 133 90.5 
White 7 4.8 
Coloured 7 4.8 
Indian 0 0 
Education 
  Primary school 68 46.3 
High school 70 47.6 
Tertiary school 9 6.1 
Income 
  None 90 61.2 
less than R500 1 0.7 
R500-R1000 4 2.7 
R1000-R2000 11 7.5 
R2000-R5000 17 11.6 
more than R5000 5 3.4 
unknown 19 12.9 
HIV status 
  Negative 83 56.5 
Positive 62 42.2 
unknown 2 1.4 
ARV treatment 
  ARV 14 22.6 
No ARV 17 27.4 
unknown 31 50.0 
Disease stage 
  Early (1-2B1) 57 38.8 
Late (2B2-4B) 69 46.9 
unknown 21 14.3 
Tumour Histology 
  Non-keratinising 
(poorly differentiated) 18 12.2 
Keratinising 
(Moderately-well differentiated) 65 44.2 
Squamous cell carcinoma 
(histology unspecified) 64 43.5 
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4.1.2 Micronucleus assay on peripheral blood lymphocytes of cervical cancer patients 
and controls 
4.1.2.1 Success rate of blood cultures and nuclear division index   
Across all collected patient samples, 45% (n = 66) had lymphocyte cultures that were 
successful for the MN assay (data for all doses or for the 0 Gy and 2 Gy dose). Reasons for 
samples not being included in the final analysis were:  
1. Poor lymphocyte proliferation (<1000 BN for 0 Gy) and/or high percentage (>25%) of 
misidentified BN ( = apoptotic/dead cells) in 2 Gy and 4 Gy. Apoptotic cells were 
those that were small, dense and brightly stained (n = 55) (37%). 
2. Technical issues, such as problems with irradiations, problems with CO2 incubator or 
small BN. Small cells were later found to be a result of low humidity during dry 
seasons in Johannesburg and could be overcome by making slides in a humidified 
area (n = 26) (18%). 
The success rate of blood lymphocyte cultures for each group were as follows: 
HIV-negative patients (n = 83): 
- Successful cultures: n = 42 (51%) 
- Poor lymphocyte proliferation and apoptotic/dead cells: n = 23 (28%) 
- Technical issues: n = 18 (21%) 
HIV-positive patients (n = 62): 
- Successful cultures: n = 24 (39%) 
- Poor lymphocyte proliferation and apoptotic/dead cells n = 32 (52%) 
- Technical issues: n = 6 (10%) 
*For two samples HIV status was not known 
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Controls (n = 91): 
- Successful cultures: n = 72 (79%) 
- Poor lymphocyte proliferation and apoptotic/dead cells: n = 6 (7%) 
- Technical issues: n = 13 (14%) 
To evaluate the quality of the MN assay, the NDI was calculated in a subset of randomly 
selected samples from each group (including both successful and unsuccessful cultures). The 
healthy controls had NDI of 2.170; 2.073 and 1.668 for the 0, 2 and 4 Gy doses. The HIV-
negative patients had NDI of 2.160; 1.842 and 1.529, while the HIV-positive patients had NDI 
of 2.074; 1.912 and 1.516 respectively. The patients combined had statistically significant 
lower NDI than controls at both 2 Gy and 4 Gy (p = 0.0091 and p = 0.0182 respectively).  
4.1.2.2 MN values in cervical cancer patients and controls and comparison of 3 scoring 
methods based on the MNScore software (Metasystems) 
The MN values of 35 cervical cancer patients (mean age = 46) were compared to 20 healthy 
controls (mean age = 41) using three different scoring methods. Fifteen of the patients were 
infected with HIV (mean age = 43) and 20 were negative for HIV infection (mean age = 49). 
Scoring methods included: 1) ‘Fully-automated’ - MN counts are based directly on those 
obtained by the MNScore module; 2) ‘Semi-automated A’ - BN with MN are checked for 
quality and false positive MN are corrected; 3) ‘Semi-automated B’ - the quality of every BN 
cell is checked and both false positive and false negative MN are corrected. Radiation-
induced MN values were calculated by subtracting background (0 Gy) MN values from MN 
values observed in irradiated cells. Background MN values and radiation-induced values for 
2 Gy and 4 Gy are listed in Table 4.2. Using the ‘fully-automated’ and ‘semi-automated A’ 
scoring method, no significant differences were detected between patients and controls. 
With the ‘semi-automated B’ scoring method, patients had significantly higher MN values at 
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both the 2 Gy (p = 0. 0075) and 4 Gy (p = 0.0059) radiation dose. The coefficient of variation 
was also lowest in the ‘semi-automated B’ method. 
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Table 4.2: MN values for controls and cervical cancer patients with 3 scoring methods. *significantly different from controls (Mann-Whitney test p<0.05). SD = standard 
deviation. SEM = standard error of the mean. CV = coefficient of variation. 
                
 
AUTOMATED   SEMI-AUTOMATED A   SEMI-AUTOMATED B 
 
 
  0Gy 2Gy 4Gy     0Gy 2Gy 4Gy     0Gy 2Gy 4Gy 
 
CONTROLS 
N 20 20 20   N 20 20 20   N 20 20 20 
 MEAN 56 125 323 
 
MEAN 10 115 317 
 
MEAN 13 155 454 
 SD 37 36 56 
 
SD 5 22 47 
 
SD 5 28 41 
 SEM 8 8 13   SEM 1 5 11   SEM 1 6 9 
 CV (%) 67 29 17 
 
CV (%) 50 19 15 
 
CV (%) 38 18 9 
 
PATIENTS 
N 35 35 35   N 35 35 35   N 35 35 35 
 MEAN 66 144 320 
 
MEAN 12 124 327 
 
MEAN 14 *179 *506 
 SD 40 56 81 
 
SD 8 26 56 
 
SD 8 33 67 
 SEM 7 9 14   SEM 1 4 10   SEM 1 5 12 
 CV (%) 61 39 25 
 
CV (%) 67 21 17 
 
CV (%) 57 18 13 
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4.1.2.3  MN values in HIV-negative cervical cancer patients, HIV-positive cervical cancer 
patients and healthy controls 
To assess the effect of HIV on chromosomal radiosensitivity and determine the 
chromosomal radiosensitivity in HIV-negative patients without HIV as a confounding factor, 
the patients were divided into HIV-positive (n = 15, mean age= 43) and HIV-negative (n = 20, 
mean age = 49) groups. Based on the results of table 4.2, the MN values were determined 
using the semi-automated B’ method. There were no differences in background MN values 
when comparing the HIV-negative (mean MN = 17) or HIV-positive patients (mean MN = 10) 
with the controls (mean MN = 13). Figure 4.1 shows the frequency distributions of the 
groups according to MN values for both the 2 Gy and 4 Gy doses. For 2 Gy, there was no 
significant difference between the mean MN values for HIV-negative cancer patients versus 
controls (p = 0.060), however there was a clear shift in the frequency distributions towards 
patients having higher MN values. The difference in mean MN values between HIV-negative 
patients and controls was significant at 4 Gy (p = 0.037). 
In HIV-positive patients, there were 2 samples with insufficient BN at the 4 Gy dose and 
were thus excluded at this dose point from the analysis. Although not statistically 
significant, the HIV-positive patients had higher MN values than the HIV-negative patients. 
73% of these patients were on ARV treatment but these did not have significantly higher 
MN values than those not on ARV treatment. The HIV-positive patients had MN values that 
were statistically higher than healthy controls at both the 2 Gy (p = 0.006) and 4 Gy (p = 
0.008) dose.  
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Figure 4.1: Radiation-induced MN values for controls, HIV-negative and HIV-positive patients after 2 Gy and 4 Gy dose of irradiation.  
Vertical line shows the mean MN value for each group. *Significantly different to controls (Mann-Whitney p<0.05). 
  
µ = 498 µ = 172 
µ = 188 µ = 519 
µ = 155 µ = 454 
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4.1.2.4 Correlation between MN values in cervical cancer patients and clinical 
parameters and age of onset 
To assess if there was a correlation between clinical parameters and chromosomal 
radiosensitivity, cervical cancer patients were divided into groups according to cancer stage 
and histology. The staging divisions were stage 1 (5 patients- 2 HIV+, 3 HIV-), stage 2 (11 
patients- 5 HIV+, 6 HIV-) and stage 3 (17 patients- 7 HIV+, 10 HIV-). The mean MN scores 
were not significantly different for any of the doses when groups were compared to each 
other (Mann-Whitney test: p>0.05). Patients were divided into 2 histology categories 
defined as non-keratinising (poorly differentiated) and keratinising (moderately and well 
differentiated). There were no differences in MN values between the groups at the 0 Gy, 2 
Gy or 4 Gy dose (Mann-Whitney test: p>0.05). 
The age of onset was significantly correlated with the background MN values of the patients 
(Pearson’s correlation, p = 0.021) No significant correlation could be found between 
radiation-induced MN and age of onset. For a second analysis to assess if age of onset had 
an influence on chromosomal radiosensitivity, patients were divided into subgroups of: 1) 
patients <40 years old (13 patients), 2) patients between 41 and 50 years old (7 patients), 3) 
patients between 51-60 years old (11 patients), 4) patients >61 years old (4 patients). There 
was a significant difference in radiation-induced MN values at the 4 Gy dose between the 
<40 years old group and the >61 years old group (p = 0.030), and <40 years old group and 
41-50 age group (p = 0.029), the young group having higher MN values. In the younger 
group 7/13 were HIV-positive, which may explain the higher MN values. There were no 
differences in MN values amongst the other age groups (Mann-Whitney: p>0.05).  
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4.1.3 γ-H2AX Foci assay on peripheral blood lymphocytes of cervical cancer patients 
The γ-H2AX assay was performed on the lymphocytes of 13 HIV-negative cervical cancer 
patients (mean age = 58) and 13 healthy controls (mean age = 46). Lymphocytes were 
irradiated with 0 Gy, 0.5 Gy and 1 Gy doses. Foci values were measured at 30 mins which 
shows initial number of induced DSB after irradiation. The number of DSB remaining after 
allowing repair for 24 hrs were also measured.  
Figure 4.2 shows individual data points of the patients and controls at each dose and time 
point. In terms of baseline foci (0 Gy), the patients had higher foci values than controls after 
30 mins but the difference was not significant. After 24 hrs, the patients had significantly 
higher baseline foci than the controls (p = 0.039). This significant difference was not reached 
if the outlier of 0.98 (seen in figure 4.2) was excluded from the dataset (p = 0.068). 
Radiation-induced foci values (mean/cell) were obtained by subtracting baseline foci values 
(mean/cell). After 30 mins, at the 0.5 Gy dose, the controls had a mean foci radiation-
induced value of 6.03 while patients had a mean foci value of 6.40 foci/cell. There was no 
significant difference. After 30 mins, at the 1 Gy dose, the controls had a radiation-induced 
mean foci value of 8.77, while patients had a mean foci value of 9.36 foci/cell. The 
difference was not significant.  
After 24 hrs, at the 0.5 Gy dose, controls and patients had a mean radiation-induced foci 
value of 0.39 and 0.40 foci/cell respectively. After 24 hrs, at the 1 Gy dose, controls had a 
mean foci value of 0.71 foci/ cell while patients had 0.86 foci/cell, the difference not being 
significant.   
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To determine the level of repair undergone by each sample, we calculated a ‘repair factor’. 
This was calculated with:  
Initial foci at a given dose - residual foci at the same given dose  X 100 
Initial foci at the same given dose 
 
Higher factors mean better repair. Controls and patients had a repair factor of 93.4% and 
93.8% at 0.5 Gy respectively. Controls had a repair factor of 91.7%, while patients had a 
repair factor of 90.7% at 1 Gy. No significant difference was found. 
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Figure 4.2: Foci values for 13 patients and matching controls. The foci for the 0.5 Gy and 1 Gy are radiation induced. *significant from 
controls at same dose and time (Mann-Whitney p<0.05). 
 
 
* 
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4.1.4 Comparison	 of	 γ-H2AX repair factor and MN values in peripheral blood 
lymphocytes of cervical cancer patients 
The MN assay was performed on the same set of samples and controls. The repair factors 
were compared to MN values as they both give information on residual damage. Table 4.3 
shows the repair factors, MN values and NDI. There was no correlation between repair 
factors and MN values for controls and patients at any of the doses. Unlike the MN assay, 
there was zero attrition of cervical cancer samples with the γ-H2AX assay. While the MN 
values were higher in patients than controls, no significant difference could be reached due 
to high attrition in the patient samples. The NDI were significantly higher in patients than 
controls at the 2 Gy and 4 Gy dose. 
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                                                                                                  Table 4.3: Comparison of repair factor in controls and HIV-negative patients with MN values and NDI. 
 
Healthy control Age repair factor % MN data NDI 
 
     0.5 Gyi 1 Gyi  0 Gy  2 Gyi 4 Gyi  0 Gy  2 Gy 4 Gy  
 
Control 1 25 96.54 96.61 11 132 438 2.4 2.2 1.9 
 
Control 2 47 95.08 94.38 7 112 388 2.2 2.0 1.7 
 
Control 3 53 91.54 86.41 15 150 539 2.0 2.1 1.6 
 
Control 4 30 94.91 93.94 4 137 455 1.7 2.1 1.8 
 
Control 5 62 92.42 88.67 20 93 296 2.1 2.0 1.6 
 
Control 6 56 93.23 87.83 4 149 497 2.3 2.0 1.6 
 
Control 7 61 93.92 91.95 11 114 336 2.1 1.8 1.5 
 
Control 8 51 91.70 92.50 10 118 428 2.4 2.2 1.9 
 
Control 9 28 97.06 90.73 8 141 569 2.3 2.1 1.5 
 
Control 10 40 89.26 88.96 8 130 390 2.2 1.9 1.9 
 
Control 11 35 91.12 93.28 2 121 363 2.4 2.0 1.6 
 
Control 12 57 96.17 93.21 17 113 475 1.9 1.6 1.3 
 
Control 13 57 91.70 93.29 14 154 604 1.8 1.7 1.4 
 
MEAN 46 93.4 91.7 10 128 444 2.1 2.0 1.6 
 
STDEV  2.4 3.0 5 18 92 0.2 0.2 0.2 
 
CV%  2.6 3.2 53 14 21 10.8 9.1 11.5 
 
Patient Age repair factor % MN data NDI 
 
    0.5 Gyi 1 Gyi  0 Gy  2 Gyi 4 Gyi  0 Gy  2 Gy 4 Gy  
 
Patient 1 37 96.44 98.37 10 144 438 2.1 2.0 1.7 
 
Patient 2 65 94.56 94.27 14 NS NS 1.9 1.6 1.5 
 
Patient 3 53 92.21 88.45 13 193 NS 2.1 1.7 1.4 
 
Patient 4 67 94.34 94.32 8 110 NS 2.2 2.0 1.4 
 
Patient 5 50 90.80 92.27 6 NS NS 2.1 1.9 1.6 
 
Patient 6 47 92.75 89.60 8 156 488 2.2 1.9 1.5 
 
Patient 7 56 90.99 86.12 10 110 409 2.2 1.8 1.5 
 
Patient 8 50 95.65 84.16 16 191 461 2.5 2.1 1.7 
 
Patient 9 68 87.88 90.79 14 174 NS 2.0 1.6 1.4 
 
Patient 10 61 97.33 89.57 NS NS NS 1.7 1.3 1.3 
 
Patient 11 70 98.49 90.03 9 105 NS 2.0 1.8 1.4 
 
Patient 12 64 93.45 90.49 26 NS NS 1.7 1.4 1.1 
 
Patient 13 63 93.99 90.16 20 177 427 2.1 1.9 1.5 
 
MEAN 58 93.8 90.7 13 151 445 2.1 1.8* 1.5* 
 
STDEV  2.9 3.6 6 36 31 0.2 0.2 0.2 
 
CV%  3.1 4.0 44 24 7 10.0 13.7 11.2                                                             NS = not suitable for reliable MN counts (insufficient BN and/or apoptotic cells) * significantly different from controls (Mann-Whitney p<0.05) 
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4.1.5 Micronucleus assay on cervical biopsy tumour cells and exfoliated cervical cells 
 
4.1.5.1 Tumour biopsy cultures 
Optimisation of tissue digestion showed the best results with Liberase Research Grade 
Purified Enzyme Blend for 4 - 12 hours. Tissue digested from endocervical biopsies showed 
cells in the squamous epithelial layers of the endocervix, particularly parabasal and 
superficial keratinocytes. Viability checking with trypan blue showed many of the cells to be 
viable after digestion. After optimisation of attachment, cells showed good attachment and 
could be cultured for up to 2 weeks before dying. Despite culturing cells in medium with 
growth factors and bovine pituitary extract which stimulates keratinocyte division, there 
was never sufficient proliferation of the cells to perform the MN assay. Figure 4.3 shows the 
attached cells under the inverted light microscope. 
 
 
Figure 4.3: Cervical biopsy cells in culture. Arrows indicate the squamous cells from different layers of the ectocervical epidermis (40x 
objective, phase contrast light microscopy). 
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4.1.5.2 Exfoliated cervical cell cultures 
Cell culture of exfoliated cervical cells was attempted on smears obtained from healthy 
women attending a colposcopy clinic. Samples were checked and any with bacterial/fungal 
infection were discarded.  Many specimens had many blood cells that could hinder growth 
of cervical cells in culture (figure 4.4). Adding an erythrocyte lysis step reduced the number 
of red blood cells without affecting morphology of exfoliated cervical cells (figure 4.4). Due 
to the thin morphology of exfoliated cervical cells, viability checking with trypan blue was 
difficult, therefore cells were stained with acridine orange (figure 4.5). In culture, cells 
showed attachment and could be maintained in culture for up to 2 weeks before dying 
(figure 4.6). Despite adding medium with growth factor and bovine pituitary extract, 
sufficient proliferation to perform the micronucleus assay could not be achieved. Many 
superficial keratinocyte cells showed pyknotic nuclei (figure 4.5) that is indicative of the 
beginning of apoptosis, which may explain the low proliferation yield. 
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Figure 4.4: Exfoliated cervical cells before and after lysis step. Red blood cells hindered exfoliated cervical cell growth in cervical smears 
(A). A lysis step reduced the number of red blood cells (B) (40x objective, phase contrast light microscopy). 
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Figure 4.5: Viability staining of exfoliated cervical cells with acridine orange.A (100X original magnification) and B (400X original 
magnification) show viable exfoliated cervical cells, however nuclei are pyknotic indicating early apoptosis. C (100X original 
magnification) and D (400X original magnification) show non-viable exfoliated cervical cells with degraded cytoplasms (10x and 40x 
objective).  
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Figure 4.6: Exfoliated cervical cells in culture. A and B show exfoliated cervical cells attached to cell culture plates (10x and 20x 
objective, phase contrast light microscopy).  
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4.1.6 Immunohistochemistry to characterise cultured cells 
Immunohistochemistry with Anti-pan Cytokeratin Antibody AE1+AE3 from abcam® was 
performed to characterise Keratinocytes in culture. The antibody was tested for specificity on 
five cervical biopsies (3 X normal ectocervix and 2 X tumour biopsies). Optimal staining was 
achieved with a citric acid buffer pre-step that allowed antigens to be better reached 
(antigen-retrieval). The antibody was shown to be specific to cervical keratinocytes (figure 
4.7).  
  
Figure 4.7: Stratified squamous epithelium of cervical ectocervix samples. A shows stratified squamous epithelium of a normal cervical 
ectocervix sample. The layers include: the basal layer (L1), parabasal layer (L2), intermediate layer (L3), superficial cells/exfoliating cells 
(L4). B shows stratified squamous epithelium of an invasive cervical cancer sample. Atypical cells from the basal layers have 
proliferated and spread into the underlying connective tissue (12.5x objective, bright field light microscopy). 
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4.1.7 Correlation of chromosomal radiosensitivity with HPV virus 
HPV typing was performed on 49 patient biopsies. Positive and negative controls typed by a 
routine laboratory with the Abbott RealTime High Risk HPV assay, for clinical purposes, were 
obtained and included in every PCR. Figure 4.8 shows examples of agarose gels with positive 
and negative controls and patient samples on which HPV typing was performed. 78% of 
biopsies were HPV positive. The most common HPV subtype was HPV 16 (52%) (figure 4.9). 
Multiple HPV subtypes in 1 sample were only present in 2 patients. 
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Figure 4.8: Agarose gel electrophoresis showing HPV genotyping with four HPV mixes.  
Numbers represent the 4 HPV typing mixes. Lanes are numbered at the top of each gel. M = marker/DNA ladder (0.1 to 1.5kb). C = 
controls. P = patient samples. N = negative for any HPV type. The internal control (test for DNA integrity) is at 99bp in every lane. 
 1)  Mix 1. Controls in lane 1= HPV 11 (472 bps)  and HPV 59 (169 bps); lane 2 = HPV 16 (397 bps) and HPV 45( 205 bps); lane 3 = HPV 16; 
lane 4 = HPV 16; lane 5 = negative control. Lanes 6 and 7 are patient samples. The patient in lane 7 is positive for HPV 16 (397 bps). 
 2) Mix 2. Controls in lane 1 = HPV 18 (187 bps); lane 2 = HPV 52 (517 bps); lane 3 = HPV 6 (263 bps) and HPV 39 (229 bps); lane 4 = HPV 
51 (299 bps); lane 5 = negative control. Lane 6 shows a patient sample that is positive for HPV 18 (187 bps).   
3) Mix 3. Controls in lane 1 = HPV 66 (277 bps); lane 2 = HPV 56 (330 bps); lane 3 = HPV 58 (414 bps); lane 4 = negative control. Lanes 5-9 
are patient samples. Lane 9 shows a patient sample that is positive for HPV 66 (277 bps). 
 4) Mix 4. Controls in lane 1 = negative control; lane 2 = HPV 33 (139 bps); lane 3 = HPV 31 (360 bps); lane 4 = HPV 35 (434 bps). Lanes 5-
7 are patient samples, none are positive for an HPV type.  
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Figure 4.9: Percentages of HPV subtypes in biopsies of cervical cancer cohort. 
 
MN data were available for 32 of these patients. For every sample there were data for the 0 
Gy and 2 Gy dose, however 4 Gy data was only available for 22 patients. There was no 
difference in the average radiation-induced MN values of lymphocytes of patients positive 
for HPV (n = 22; 0Gy =12; 2Gy = 178, 4Gy = 471) compared to those negative for HPV (n = 
10; 0Gy = 13; 2Gy = 186, 4Gy = 500). There was also no significant difference in the 
radiation-induced MN values of patients infected with subtypes 16 and 18 (most high risk 
subtypes), others combined, or negative (figure 4.10). There was also no difference in MN 
values between the α7 and α9 HPV subtypes (Hall et al., 2013). 
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Figure 4.10: MN values in patients according to HPV subtypes. Error bars = SEM 
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4.2 Breast cancer patients 
4.2.1 Study population 
One hundred and thirty seven breast cancer patients were recruited during the study. Table 
4.4 shows the biographical characteristics of this cohort. Black breast cancer patients 
showed the earliest age at diagnosis and were significantly younger than white and Indian 
patients. Coloured patients were also significantly younger than white patients. Black and 
coloured patients also had the highest level of ‘pre-menopausal’ breast cancer. The highest 
level of education and income was seen in white and Indian patients. HIV positivity was only 
seen in black and coloured patients.  
Table 4.5 summarises the tumour characteristics of the patients. Black patients presented 
with the largest tumours, and along with coloured patients had significantly larger tumours 
than white patients. There was no difference in histology amongst the groups, ductal 
carcinoma being the commonest in all. Black patients had the highest percentage of stage 3 
tumours. Coloured and Indian women had the highest percentage of estrogen-negative 
tumours, while coloured and black had the highest percentage of progesterone-negative 
tumours. Coloured patients also had the highest percentage of HER2-negative tumours. 
While there were differences in percentages of receptors, the difference was not significant 
(Chi-squared p>0.05). 
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                      Table 4.4: Characteristics of breast cancer patients. 
Characteristic Black (%) White (%) Coloured (%) Indian (%) p-value 
Number of patients 65 (47.4) 54 (39.4) 5 (3.6) 13 (9.5)  
Age at diagnosis 48 62 60 55 p<0.001* 
Menopause 
    
 
Pre-menopausal 31 (48.4) 5 (9.4) 3 (60) 4 (30.8) P<0.001** 
Post-menopausal 30 (46.9) 44 (83) 2 (40) 7 (53.8)  
Hysterectomy 3 (4.7) 4 (7.5) 0 2 (15.4)  
unknown 1 1 0 0  
Education 
    
 
Primary school 14 (21.9) 2 (3.9) 0 3 (23.1) P=0.008** 
High school 36 (56.3) 28 (54.9) 5 (100) 9  (69.2)  
Tertiary school 14 (21.9) 21 (41.2) 0 1 (7.7)  
unknown 1 3 0 0  
Income 
    
 
None 30 (48.4) 17 (38.6) 3 (60) 7 (53.8) p=0.049** 
<5000 ZAR 18 (29.0) 6 (13.6) 1 (20) 0  
>5000 ZAR 14 (22.6) 21 (47.7) 1 (20) 6 (46.2)  
unknown 3 10 0 0  
HIV-status 
    
 
Positive 11 (20) 0  1 (25) 0  p=0.008** 
Negative 44 (80) 40 (100) 3 (75) 11 (100)  
unknown 10  14  1 2   
   Percentages calculated without taking missing data (unknown) into account 
*ANOVA statistical test 
** Chi-squared statistical test 
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Table 4.5: Tumour characteristics of breast cancer patients according to ethnicity 
 
Characteristic Black (%) White (%) Coloured (%) Indian (%) p-value 
Tumour size mm (average) 29 20 37 24 P=0.025* 
Histology (%) 
    
 
Ductal 38 (84.4) 32 (76.2) 4 (100) 7 (63.6) P> 0.05** 
Lobular 3 (6.7) 3 (7.1) 0 2 (18.2)  
In situ Ductal/Lobular 3 (6.7) 7 (16.7) 0 2 (18.2)  
Other  1 (2.2) 0 0 0  
unknown 20 12 1 2  
Disease stage (%) 
    
 
0 1 (2.4) 2 (5.9) 0  1 (11.1) p>0.05** 
1 4 (9.5) 8 (23.5) 1 (25) 2  (22.2)  
2 22 (52.4) 18 (52.9) 3 (75) 5 (55.6)  
3 15 (35.7) 6 (17.6) 0  1 (11.1)  
4 0 0 0 0  
unknown 23 20 1 4  
Tumour grade (%) 
    
 
1 8 (18.2) 9 (22.5) 0 3 (30) p>0.05** 
2 21 (47.7) 14 (35) 3 (75) 4 (40)  
3 15 (37.4) 17 (42.5) 1 (25) 3 (30)  
unknown 22 14 1 3  
Estrogen receptors (%) 
    
 
Positive 39 (84.8) 35 (87.5) 3 (75) 8 (72.7) p>0.05** 
Negative 7 (15.2) 5 (12.5) 1 (25) 3 (27.3)  
unknown 19 14 1 2  
Progesterone receptors (%) 
   
 
Positive 29 (63) 31 (79.5) 3 (75) 7 (63.6) p>0.05** 
Negative 17 (37) 8 (20.5) 1 (25) 4 (36.4)  
unknown 18 15 1 3  
HER2 receptors (%) 
    
 
Positive 10 (22.2) 8 (22.9) 0 4 (36.4) p>0.05** 
Negative 35 (77.8) 27 (77.1) 4 (100) 7 (63.6)  
unknown 20 19 1 2  
 
 
Percentages calculated without taking missing data (unknown) into account 
*ANOVA statistical test 
** Chi-squared statistical test 
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4.2.2 Micronucleus assay on peripheral blood lymphocytes of breast cancer patients 
and controls 
The radiation-induced MN values of 49 breast cancer patients (mean age = 49) and 52 
healthy controls (mean age = 37) were compared. The MN values were determined with the 
‘Semi-automated B’ method based on the results obtained for the cervical cancer patients. 
There was no significant difference between patients and controls at 0 Gy, 2 Gy and 4 Gy (p 
= 0.068). The patients and controls were split into groups according to ethnic groups which 
included: 1) Black group (20 patients - mean age = 48; 18 controls - mean age = 35). 2) 
Coloured group (4 patients - mean age = 45; 5 controls - mean age = 34). 3) Indian group (8 
patients - mean age = 45; 5 controls- mean age = 35). 4) White group (17 patients - mean 
age = 59; 24 controls -mean age = 39). Figure 4.11 shows the radiation-induced MN yields 
for each ethnicity at 2 Gy and 4 Gy doses. There was no significant difference in radiation-
induced MN between controls and patients except in the white group at the 4Gy dose (p = 
0.027). 
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Figure 4.11: Comparison of radiation-induced MN frequencies between patients and controls across the 4 ethnic groups. * significantly different from controls (Mann-Whitney p<0.05). Error bars = SEM. 
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4.2.3 Correlation between MN values in breast cancer patients and clinical parameters 
and age of onset 
No correlation was found between age and MN values (p>0.05, Pearson’s correlation). For a 
further analysis, all breast cancer patients were divided into subgroups. These were the 
same groups as for the cervical cancer patients. 1) patients <40 years old (10 patients), 2) 
patients between 41 and 50 years old (12 patients), 3) patients between 51-60 years old (14 
patients), 4) patients >61 years old (12 patients). There were no significant differences in 
radiation-induced MN values between the different age groups at any dose points (Mann-
Whitney test p>0.05).  
All the breast cancer patients were also split into groups according to clinical parameters 
and MN values in these groups were compared. There was no difference in MN values 
according to menopausal status of women. There was also no difference between groups 
with different tumour histology types. For tumour size, groups were split into groups (>2cm 
and <2cm). No differences were found in MN values between the groups. There was also no 
difference in MN values according to tumour stage and HER2 receptor. At the 2 Gy dose, 
there was an effect of estrogen receptor positivity (p = 0.039) and progesterone receptor 
positivity (p = 0.028). Those positive for the receptors having higher MN values. 
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5 Discussion 
5.1 Cervical cancer patients 
One hundred and forty seven cervical cancer patients with squamous cell carcinomas were 
recruited throughout the study. Major exclusion factors were previous treatment with 
chemotherapy or radiotherapy and blood transfusions, which are often given to cervical 
cancer patients to treat anaemia. Baeyens et al., (2010) showed that samples with CD4 
counts below 300 cells/mm3 were not suitable for the performance of the micronucleus 
assay so this was another exclusion factor for HIV-positive patients. The characteristics of 
this cohort in this study are similar to what has previously been described in other South 
African studies (Lomalisa et al., 2000, Moodley et al., 2001, Nyongesa et al., 2006, Denny et 
al., 2014), especially regarding the majority of patients presenting with late-stage disease 
and HIV-positive patients being 10 years younger than HIV-negative patients (Lomalisa et al., 
2000, Moodley et al., 2001). A striking contrast in our cohort was the high level of HIV 
positivity amongst patients. Forty-two percent of patients were HIV-positive, compared to 
Lomalisa et al., (2000) who saw 7.2%, Moodley et al., (2001) 21% and Denny et al., (2014) 
24.6%. This cannot be explained by increased HIV-positivity in the overall South African 
population, which was 10.2% in 2014 (STATSA, 2014).  
The first aim of the study was to perform the MN assay on lymphocytes of cervical cancer 
patients and controls and validate the different scoring methods with the MNScore software 
of the Metafer (Metasystems). The Metafer has been used in two similar population studies 
on breast and prostate cancer (Varga et al., 2005, Varga et al., 2006). Using automated MN 
scores only, Varga et al. (2005, 2006) were able to distinguish clearly between breast cancer 
patients and controls but not between prostate cancer patients and controls. In our study, a 
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significant difference in MN after both 2 Gy and 4 Gy was only seen between patients and 
controls with the ‘semi-automated B’ scoring method which requires every BN selected by 
the Metafer system to be checked by a scorer. We noticed that factors hindering the other 
two scoring methods included apoptotic cells, missing of MN if there were many in a cell 
and cell debri.  
Apoptotic cells, cell debri and a wide cell size range have been mentioned in other studies as 
factors impairing the efficiency of the Metafer system (Bolognesi et al., 2011, Fenech et al., 
2013). The cancer population in this study was of mostly late-stage disease, which can 
contribute to the presence of apoptotic cells. We noticed that two apoptotic cells of similar 
size in close proximity were often mistaken as a BN cell by the MNScore software. These 
apoptotic cells could be identified by the scorer as they were smaller, denser and more 
brightly staining than nuclei of non-apoptotic cells. Adjusting the classifier may have 
ameliorated this problem but the classifier used also for the breast cancer samples was 
maintained so both cancer groups could be compared with the same controls. Two 
apoptotic cells in close proximity were sometimes misidentified as BN and were rejected 
when scoring with the ‘semi-automated B’ method. Samples with a high level of apoptosis 
(>25% rejection of cells with ‘semi-automated B’ scoring in 2 and 4 Gy) were excluded from 
the final analysis. In samples with moderate apoptosis, checking every BN and rejecting 
misidentified BN allowed for more reliable MN counts. 
It has been noted in another study, using automated scoring only, that the system may fail 
in detecting all MN in a cell if they are close to or attached to the main nuclei and that the 
fully automated scoring may fail to count all MN if there are many MN in the same cell 
(Fenech et al., 2013). The in vitro doses administered in our study resulted in multiple MN, 
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which were missed with the ‘fully-automated’ and ‘semi-automated A’ scoring method but 
could be counted with the ‘semi-automated B’ method. Cell debri on slides was also noticed 
as a factor hindering the ‘fully-automated’ scoring due to many false positive MN, however 
these could be corrected with the ‘semi-automated B’ method. While ‘semi-automated B’ 
scoring on the Metafer does take longer than the other two methods, it is still quicker than 
scoring manually under a microscope. An additional benefit of the automated system is the 
image gallery that can be archived as a ‘virtual slide’ and re-analysed later. The ‘semi-
automated B’ method may be the more suitable/reliable method when performing 
radiosensitivity studies in late-stage disease cancer populations. 
The next aim was to compare chromosomal radiosensitivity in HIV-positive and HIV-negative 
cervical cancer patients with healthy controls. In the HIV-negative group, at a 2 Gy dose, the 
difference was not significant but there was a clear shift in the frequency distributions of 
MN counts being higher in patients than controls. The difference between patients and 
controls became significant at 4 Gy. Previous studies on chromosomal radiosensitivity in 
lymphocytes of HIV-negative cervical cancer patients with the MN assay have been 
inconclusive. In a study by Ban et al. (2004), patients were found to have lower radiation-
induced MN frequencies than controls. However, blood samples in a large proportion of the 
patients were taken after or during radiotherapy treatment. This resulted in high 
spontaneous MN values which affect radiation-induced MN values. It was also suggested by 
the authors that the lower MN values seen in cervical patients may be the result of “an 
adaptive-response like phenomenon” from the in vivo therapy. A study similar to ours was 
performed by Encheva et al. (2011), where MN values in lymphocytes in 40 gynaecological 
patients (23 cervical and 17 endometrial combined into one group) were compared to those 
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obtained in 10 healthy controls. They found similar MN values for the combined 
gynaecological patients and the controls after exposure to an in vitro dose of 1.5 Gy. The 
inclusion of 17 patients with endometrial cancer, however, makes it difficult to draw 
conclusions on the chromosomal radiosensitivity of cervical cancer patients alone. 
The increased MN values of HIV-negative cervical cancer patients compared to controls in 
our study suggests increased chromosomal radiosensitivity. Despite cervical cancer being 
caused primarily by infection with HPV, inherited genes are believed to play a role in cervical 
cancer susceptibility as only a fraction of women with HPV progress to disease. The disease 
also shows familial clustering (Magnusson et al., 1999). While immune response genes have 
been of focus in cervical cancer research, (Chen et al., 2013, Jiang et al., 2013, Chen et al., 
2014), recent reports have shown associations between DNA damage repair genes and 
cervical cancer risk (Wang et al., 2010, Oliveira et al., 2012, Bajpai et al., 2013, Perez et al., 
2013, Wang et al., 2013). Additionally, studies have shown Fanconi Anemia (FA) patients 
(patients with deficient DNA damage repair mechanisms) to be more susceptible to HPV-
positive head and neck squamous cell carcinomas compared to non-FA patients with the 
same lesions (Kutler et al., 2003). Park et al. (2010) showed that there is an interplay 
between HPV and the FA pathway. The exact role of DNA damage repair genes and cervical 
cancer is still unclear. Evidence from studies using retroviruses shows that when a virus 
integrates into the host genome, a double strand break is formed, causing a DNA damage 
response similar to that seen when cells are exposed to ionising radiation (Skalka and Katz, 
2005). If these DSB are not repaired and the integration process is not properly regulated, it 
can result in genomic instability which can lead to carcinogenesis (Oliveira et al., 2012). 
Research has also shown that HPV’s preferential targets of integration are fragile sites 
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(Thorland et al., 2003). DNA damage repair genes like ATR, BRCA1, Checkpoint kinase 1 
(CHEK1), have been shown to play a role in fragile site stability (Casper et al., 2002, Arlt et 
al., 2004, Glover et al., 2005, Durkin et al., 2006). There may be a link between 
compromised DNA damage repair, fragile sites stability and susceptibility to HPV integration 
and subsequent carcinogenesis. 
HIV-positive cervical cancer patients had higher MN values than HIV-negative cervical cancer 
patients, despite the difference not being significant. The HIV-positive patients had MN 
values that were significantly higher than the healthy controls at 2 Gy and 4 Gy, which 
confirms the results of Baeyens et al. (2010). Our results highlight that when doing studies in 
developing countries, factors like HIV should be considered. Evidence suggests that these 
patients suffer from increased side-effects after radiotherapy but further investigation is 
required to confirm this (Shrivastava et al., 2005, Gichangi et al., 2006, Housri et al., 2010). 
The reason for higher MN counts in HIV-positive individuals is not known. Studies have 
shown HIV proteins like Viral Protein R (Vpr) and Integrase to interact with host DNA 
damage repair proteins (Bouhamdan et al., 1996, Ha et al., 2001, Mulder et al., 2002, 
Cooper et al., 2013), however this hypothesis is not yet fully clear (Ariumi et al., 2005). Vpr is 
also known to play a role in cell cycle regulation and can arrest cells in the G2 phase which 
can influence DNA damage repair (Amini et al., 2004). It has been shown recently that 
antiretroviral treatment influences MN counts in cancer-free HIV-positive individuals (Herd 
et al., 2014b). Since 73% of the HIV-positive patients included in the MN analysis were on 
ARV, it is possible that this had an influence on the MN results. Patient files were primarily 
focused on cervical cancer treatment, therefore information on the type and duration of 
antiretroviral treatment was often not specified. Interesting future studies would be to 
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compare chromosomal radiosensitivity in HIV-positive cervical cancer patients with and 
without ARV to determine the effect of ARV on radiosensitivity in these patients. 
A challenge encountered in our study was to efficiently stimulate the lymphocytes of 
cervical cancer patients to perform the MN assay. In many samples, there were not enough 
BN, or there was a high level of apoptosis by which these samples could not be included in 
the final analysis. This occurred in both HIV-negative and HIV-positive patients but more so 
in the latter group. When comparing the NDI of a set of samples from the HIV-negative, HIV-
positive and control groups, patients (HIV-negative and HIV-positive) had significantly lower 
NDI’s than controls after irradiation, with HIV-positive patients having the lowest NDI’s, 
illustrating the decreased proliferation capacity of patient lymphocytes. This was likely due 
to arrest in G1 as the cells were irradiated in the G0 cell cycle and it would appear that the 
doses administered resulted in a high level of DNA damage that caused the cells to enter 
into apoptosis (Saini et al., 2012). Cervical cancer cells produce a cytokine, Transforming 
growth factor beta (TGF-β), that has been shown to inhibit lymphocyte proliferation 
(Alcocer-Gonzalez et al., 2006, Diaz-Benitez et al., 2009, Lopez-Munoz et al., 2013). The 
production of this cytokine increases with increasing malignancy (Peghini et al., 2012). 
Production of TGF-β is related to HPV infection, as cervical cancer cell lines transformed 
with HPV express this cytokine at greater levels than those without HPV (Alcocer-Gonzalez 
et al., 2006, Diaz-Benitez et al., 2009). Lopez-Munoz et al., (2013) showed that CD4 
lymphocytes from healthy people cultured in the same medium that had previously been 
used to culture cervical cancer cell lines (conditioned medium), had reduced proliferation 
after addition of phytohaemagglutinin. The study also showed that the conditioned medium 
induced apoptosis of the lymphocytes. Diaz-Benitez et al., (2009) also saw reduced 
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proliferation after phytohaemagglutinin in lymphocytes of cervical cancer patients 
compared to controls. A study by Jain et al., (1990) found a significant decrease in CD4 
lymphocytes in patients with increasing cervical lesions. Since many of the patients in our 
study were of late-stage disease, expression of immunosuppressive cytokines like TGF-β by 
cervical cancer cells is a possible explanation for the low level of stimulation of lymphocytes, 
especially in the HIV group who already have compromised CD4 cells. The anti-proliferative 
and apoptotic effect of TGF-β on CD4 cells described in the studies of Lopez-Munoz et al., 
(2013) and Diaz-Benitez et al., (2009) could not be demonstrated for CD8 cells. The same 
was noted by Jain et al., (1990) who saw an increase in the CD8 subset, resulting in lower 
CD4/CD8 ratios with increasing cervical cancer malignancy. This is important to keep in mind 
in radiobiology studies as different T-lymphocyte sub-populations exhibit different 
radiosensitivities and CD8 cells have been found to be the most sensitive (Wuttke et al., 
1993, Wilkins et al., 2002a, Wilkins et al., 2002b, Vokurkova et al., 2006). This is particularly 
relevant when interpreting the MN data in HIV-positive patients who are likely to have the 
lowest CD4/CD8 ratios due to the combined effect of HIV and TGF-β on CD4 cells. Since only 
CD4 counts are tested in patients at our hospital, the ratio of CD4/CD8 at the time of taking 
blood could not be determined. Radiotherapy has been shown to decrease CD4 counts in 
both HIV-negative and HIV-positive individuals (Sankatsing et al., 2013). The high doses 
given in this study could have affected CD4 counts and may be a contributing factor to high 
level of apoptosis and ‘fall-out’ at the 4 Gy dose. Another aspect to mention with regard to 
HIV-positive patients and lymphocyte proliferation is HIV Vpr protein causing G2/M cell 
cycle arrest (Amini et al., 2004). This could be a contributing factor to the difficulty in 
stimulating the lymphocytes of these patients (Baeyens et al., 2010).   
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The third aim of the study was to assess if chromosomal radiosensitivity was influenced by 
clinical parameters and age of onset of the disease. Despite the groups being small, our 
results show that there were no differences in MN values between groups according to 
tumour stage and histology. While correlations have been observed between MN values 
and response to treatment (Slonina and Gasinska, 1997), literature on correlation between 
MN values in cervical cancer patients and clinical parameters is scarce. In our study we 
observed a difference in MN values between the youngest (<40 year old) age group and age 
groups 41-50 and >60, however the higher MN values in the young group may have been 
influenced by the high percentage of HIV-positivity in this group. There was also a 
correlation between patient age and background MN values (0 Gy), which has been well-
established in many studies (Fenech and Bonassi, 2011). 
Besides the MN assay, we also performed the γ-H2AX foci assay on lymphocytes of 13 HIV-
negative cervical cancer patients and controls. This test, performed 30 mins and 24 hrs post 
irradiation, measures DNA double strand break induction and residual damage after repair, 
while the MN assay measures chromosomal damage resulting from mis/non-repaired DSB. 
Elevated γ-H2AX foci counts have been detected in lymphocytes of lung cancer (1 hr post-
irradiation, 2.5 Gy dose) and bladder cancer (1 hr post-irradiation, 2.5 Gy dose) cohorts 
compared to controls after in vitro irradiation (Fernandez et al., 2013, He et al., 2013). A 
study performed on breast cancer patients showed a significantly higher number of γ-H2AX 
foci in patients compared to controls at 0.5 Gy after 30 mins and at 2 Gy after 24 hrs 
(Djuzenova et al., 2013). To our knowledge, γ-H2AX foci have not been investigated in a case 
control-study design in lymphocytes of cervical cancer patients. In our study, this was 
performed on HIV-negative patients only, as HIV was shown to have an effect on 
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chromosomal radiosensitivity in the MN assay. Regarding baseline foci, there was no 
difference between patients and controls after 30 mins of incubation. Patients showed a 
trend of higher mean foci values after 24 hrs incubation, however, the difference was not 
significant after removing one outlier. The reason for the higher level of DNA double strand 
breaks in this outlier is not known. The number of radiation-induced foci measured 30 mins 
after irradiation was similar between patients and controls with no significant difference 
between both groups at both doses. Foci were measured 24 hrs post-irradiation to compare 
residual foci in patients and controls after allowing for repair. There was no significant 
difference at both doses. There were also no difference in the repair factors between the 
groups.  
The outcome of this assay was not in agreement with the MN assay performed on 35 
patients where there was a clear difference between patients and controls. There was also 
no correlation between the repair factors and MN values performed on the same set of 
samples. Vandersickel et al., (2010) failed to see increased residual foci values in a repair-
deficient breast cancer cell line compared to a repair-proficient one, while a significant 
increase in MN values was observed. The authors suggested that mis-rejoined breaks will 
not be detected by the γ-H2AX foci assay. Mis-rejoined breaks, which would cause foci to 
disappear, could result in micronuclei. This may be a possible explanation for the different 
outcomes between the two assays. Other studies have also found a lack of concordance 
between MN values and γ-H2AX foci (Yoshikawa et al., 2009), while some show agreement 
between the different endpoints of the 2 assays (Eastham et al., 2001, Scarpato et al., 2011). 
Another reason for not detecting differences between the groups is that at low doses like 
0.5 Gy and 1 Gy the number of remaining DSB become too low to see significant differences. 
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Interesting further studies would be to repeat what was done here using 2 Gy and 4 Gy 
doses. At 30 mins, γ-H2AX foci could not be counted at such high doses but could give more 
information on differences in remaining damage after allowing for repair. This may also 
result in a better correlation between repair factors and MN values as the radiation doses 
would be the same. Additionally, repair kinetics studies, in which foci are counted at several 
different time points after irradiation may give more information on differences in repair. 
When comparing the practicalities of the two tests, unlike the MN assay, there was zero 
attrition of samples with the foci assay, and an advantage of the assay is that it does not 
require dividing cells which overcomes the problem of low stimulation and apoptotic cells in 
cervical cancer lymphocytes. However, disadvantages of this is it is more labor intensive and 
costly than the MN assay and places a greater burden on the Metafer 4 system (±1.5 hrs per 
slide compared to ±8 mins per slide for 2000 cells). The fluorescent stain also fades with 
time, so slides need to be scanned shortly after the immunostaining and cannot be stored 
long-term.  
Another aim of the study was to develop a MN assay that could be performed on cervical 
biopsy tumour cells and exfoliated cervical cells of cervical cancer patients. Cell cultures 
from cervical tissue are traditionally established using 3T3 feeder cells (Coleman et al., 1993, 
Freshney, 2010), however, a few studies have successfully established cervical cell lines 
without feeder cells (Koopman et al., 1999, Widel et al., 1999, Brink et al., 2002, Darroudi et 
al., 2010). Widel et al., (1999) was able to perform the MN assay on irradiated biopsies, 
which was shown to have predictive value. The protocol of our study was modelled on that 
of Widel et al., (1999), Brink et al., (2002) and Darroudi et al., (2010) with some added 
modifications according to Freshney et al., (2010). These protocols were tested and 
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optimised on our samples. Despite achieving adequate cell digestions and cell attachment, 
and using mediums suggested by the above-mentioned protocols, cells could be maintained 
in culture for up to two weeks, but there was never sufficient proliferation to allow for 
enough BN to perform the MN assay. A major challenge encountered in this part of the 
work was the high number of late-stage disease patients. Many tumours from patients 
consisted of necrotic tissue and there was a high level of apoptosis and cells with poor 
morphology which hindered culturing and proliferation of the cells.  
In some studies baseline micronuclei have been measured in un-stimulated exfoliated 
cervical cells and in general a correlation is observed between MN frequency and cervical 
cancer lesions (Leal-Garza et al., 2002, Samanta et al., 2011). Since the aim of this part of the 
study was to perform the MN assay in exfoliated cervical cells, we did not measure MN in 
un-stimulated cells. To our knowledge, exfoliated cervical cells have never been cultured. 
Like the cervical biopsies, despite many optimisations resulting in successful attachment and 
maintenance in culture, there was not enough division of these cells to allow for the MN 
assay. A possible reason is that these cells, being exfoliating cells, are very well 
differentiated with pyknotic nuclei (characteristic of apoptosis) when they reach the outer 
layers of the ectocervix. This may hinder their ability to proliferate in culture. 
The final aim of our study performed on cervical cancer patients was HPV typing on patient 
tumour biopsies to correlate with MN data. Seventy eight percent of biopsies were positive 
for the HPV virus. This is lower than in other studies on South African cohorts, (Moodley et 
al., 2010, Denny et al., 2014) but this group is small and not representative of the overall 
population due to selection criteria of the study, for example, exclusion of patients who 
underwent a blood transfusion or patients with low CD4 counts. It was also only performed 
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on a sub-set of patients who agreed to give a biopsy for research purposes. Different HPV 
subtypes have been shown to produce proteins that have differing affinity for host p53 
protein (Lechner and Laimins, 1994). If there is a link between DNA damage repair genes 
and susceptibility to HPV and cervical cancer, it is reasonable to hypothesise that 
compromised DNA repair may be correlated to HPV positivity or potentially to specific HPV 
subtypes. Our results suggest that MN values are not correlated with HPV infection or 
subtype or α7 and α9 subtypes. There was also no difference in background MN values 
suggesting no link between chromosomal instability, as determined with the MN assay, and 
susceptibility to HPV integration. 
5.2 Breast cancer patients 
In our study, similar trends were seen in the characteristics of the breast cancer cohort to 
what has previously been described in South African breast cancer populations (Cubasch et 
al., 2013, Herd et al., 2014a). The data in this study showed how characteristics of breast 
cancer can differ amongst different ethnic groups. For example, black women were 
significantly younger than other groups and had a significantly higher proportion of pre-
menopausal patients. This trend also occurs in studies done on American breast cancer 
patients of different ethnicities (Clarke et al., 2012). Black and coloured women had 
significantly larger tumour sizes and a higher proportion of patients presenting in stage 3. 
Both tumour size and stage are linked with poorer disease outcome (Chagpar et al., 2011). 
The differences between the ethnic groups points to differences in the underlying biology of 
the disease and led to the idea of comparing chromosomal radiosensitivity in different 
ethnic groups. 
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Although many studies have shown breast cancer patients to be more chromosomally 
radiosensitive than controls (Scott et al., 1994, Terzoudi et al., 2000, Riches et al., 2001, 
Baeyens et al., 2002, Varga et al., 2006, Poggioli et al., 2010, Ryabchenko et al., 2012, 
Djuzenova et al., 2013), chromosomal radiosensitivity has never been assesed in a 
population residing in Sub-Saharan Africa. In our study, chromosomal radiosensitivity was 
analysed in 49 South African breast cancer patients and 52 healthy controls. The patients 
showed higher MN values at both the 2 Gy and 4 Gy dose but the difference was not 
significant for either dose. There was also no difference in spontaneous MN values. When 
dividing the patients into different groups based on ethnicity, higher MN values were 
observed in the black patient group, but the difference was not significant at any dose. In 
the white patient group, patients had higher MN values than the controls and the difference 
was significant at 4 Gy. The coloured patients had the highest MN values. Interestingly, the 
Indian patients had lower MN values than controls. These last two groups, however, were 
very small so no conclusions can be drawn based on these data. Our results in the white 
patient group showed elevated chromosomal radiosensitivity which confirms those of other 
studies on white patients. It is interesting that the same was not seen in black breast cancer 
patients. In a study performed by Wang et al., (2012) looking at chromatid breaks in young 
breast cancer patients, a similar trend was observed. They found significantly higher 
chromatid breaks in white and Mexican American women but no difference in Africa-
American women. African breast cancer patients are known to have aggressive tumour 
phenotypes compared to European women and a higher prevalence of triple negative and 
premenopausal breast cancers. Understanding the underlying mechanisms in this group is of 
importance. Results indicate that in terms of DNA damage repair genes and breast cancer, 
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there may be a difference between women of European and African descent, however 
further studies are needed to validate this.  
The effect of clinical parameters on chromosomal radiosensitivity was also investigated. We 
found no effect of menopause status on MN values of all breast cancer patients combined. 
The study of Riches et al., (2001) also did not detect an effect of menopause status on 
chromatid breaks in lymphocytes in the G2 phase. However, Baeyens et al., (2005a) found 
that pre-menopausal women were more chromosomally radiosensitive than post-
menopausal women . A similar trend was noted by Ryabchenko et al., (2012). There was an 
effect of estrogen and progesterone receptor status on MN values at the 2 Gy dose, with 
receptor positive women having significantly higher MN values. A similar trend was 
observed in the study of Riches et al., (2001) where patients with increased G2 
radiosensitivity had a higher proportion of ER receptor positive tumours. In the study of 
Baeyens et al., (2005b) no effect on MN values of in vivo and in vitro estrogen levels were 
observed . Other studies, however, have shown that hormones can affect chromosomal 
radiosensitivity (Ricoul et al., 1997). Since we did not measure the level of blood 
estrogen/progesterone in patients, it is not possible to comment if it is changes in these 
hormones, related to receptor status, that may be affecting the MN counts. No relationship 
was seen between chromosomal radiosensitivity and HER2. There was also no effect of 
tumour histology or tumour size or stage on MN yields. Also no difference was observed in 
MN values between age groups, this in agreement with Baeyens et al., (2005a). 
5.3 Conclusion 
The overall aim of the study was to investigate the chromosomal radiosensitivity of South 
African cervical and breast cancer patients. Our results suggest increased chromosomal 
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radiosensitivity in cervical cancer patients with the MN assay. Using the γ-H2AX assay, no 
difference was seen between patients and controls showing a lack of agreement between 
the endpoint of these two assay. Further studies are needed to unravel the link between 
chromosomal radiosensitivity, DNA damage repair genes and the underlying mechanisms of 
susceptibility to HPV-induced carcinogenesis. These could lead to a marker for increased 
cancer risk in women with HPV infections and could assist in prioritising those needing 
regular Pap smears which is helpful in resource-limited countries such as South Africa.  Our 
findings confirm that cervical cancer patients seeking radiotherapy who are HIV-positive 
may form a distinct group that require individualised treatments. Our study also showed the 
benefits and challenges of using the MN and γ-H2AX foci assay on lymphocytes of late-stage 
disease patients. The scoring method introduced in this study for the automated MN assay 
may be of benefit to future research projects on late-stage cancer populations. 
Results on the breast cancer patients confirmed those of overseas studies on women of 
European descent. However, the same was not seen in women of other ethnicities. This 
study highlights how different genetic mechanisms may underlie breast cancer risk in 
women from different genetic/ethnic backgrounds. Further studies are needed on African 
populations to further delineate unique genes/polymorphisms at play in breast cancer risk. 
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7 APPENDIX A: Copy of publications emanating from this thesis 
Ethnical differences in breast cancer characteristics in South African population 
1,2O. Herd, 1,2F. Francies, 3A. Cairns, 1X. Muller, 1J.P. Slabbert, 1,2A. Baeyens 
1iThemba LABS, Dept Radiation Biophysics, Somerset West, South Africa; 
2Radiobiology, Dept Radiation Sciences, University of Witwatersrand, Johannesburg, South 
Africa; 
3Dept Surgery, University of Witwatersrand and Donald Gordon Medical Centre, 
Johannesburg, South Africa 
 
Breast cancer is the most common cancer amongst South African women, with the National 
Cancer Registry of South Africa estimating a 1 in 32 lifetime risk of developing the disease 
(1).  South Africa is a country with diverse ethnic groups and the lifetime risk of developing 
breast cancer differs according to ethnicity. The lifetime risk is 1/53 in black women, 1/15 in 
white women, 1/21 in coloured women and 1/20 in Indian women (1). The incidence of 
breast cancer is on the rise in South African women. This is typically due to increased life 
expectancies and urbanisation that leads to lifestyle changes that elevate exposure to 
known risk factors for breast cancer (2). The mortality rate of existing South African breast 
cancer patients is high owing to limited access to diagnostic centers in rural areas, lack of 
awareness, lower standards of healthcare facilities and limited screening (3). 
Studies elucidating the characteristics and underlying markers of breast cancer are of 
importance as they can guide breast cancer prevention strategies, patient management and 
the development of novel treatments. These types of studies are especially important in 
countries like South Africa for the following reasons:  
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1) Women of African ancestry are shown to have more aggressive tumour phenotypes 
compared to European women and triple negative and premenopausal breast cancers are 
believed to be more prevalent  
2) South Africa also has a large mixed-race (‘coloured’) population about which, in terms of 
breast cancer characteristics, little is documented  
3) Breast cancer in South Africa occurs within the backdrop of a high prevalence of HIV 
infection. The exact role that HIV plays in breast cancer incidence, underlying tumour 
biology or patient response, is not yet entirely clear.   
The socioeconomic factors and biological characteristics of 233 South African breast cancer 
patients from Johannesburg in relation to ethnicity were investigated (Table 1 and Table 2). 
The Chi square test was used to compare the differences in characteristics between the 4 
ethnic populations.  
The cancer cohort consisted of 55% black, 30% white, 6% coloured and 9% Indian women. 
The black women were statistically significantly younger than the other 3 groups. 34% of 
black women were pre-menopausal compared to 10% of white women, 23% of coloured 
women and 15% of Indian women. These findings are consistent with studies done on 
American breast cancer patients with different ethnicity (4).  
Large distributions of income and education levels amongst patients were noticed and 
income / education levels were significantly associated with the age at diagnosis and 
menopausal status regardless of ethnicity. 
The black and coloured women had the significantly (p<0.001) largest tumour sizes. As 
Chagpar et al. (5) suggested that tumour size is a driving force of poorer disease outcome, 
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improved and early screening is especially important for the black and coloured South 
African women. The majority of patients presented with moderate/poorly differentiated 
tumours (grade 2 -3) and this was similar over all the ethnical groups. However, 46% of the 
black patients were diagnosed in stage III or IV compared to 27% or less in women from 
other groups. Late stage disease is linked with a worse prognosis. In this study the late stage 
of the disease was significantly linked with lower income level (p<0.001) across the different 
ethnical groups. 
Another factor influencing prognosis and treatment is the presence of hormone receptors. 
Black and coloured women presented with a higher incidence of ER- and PR- negative 
tumours. On the contrary, Her2- tumours occurred mostly in white and coloured women.  
18% of our black breast cancer patients were HIV positive but their tumour characteristics 
did not differ significantly with those of the HIV negative patients.  
Our study showed that ethnical differences occur in South African breast cancer patients. 
No factor could be exclusively responsible for the observed differences but income and 
education levels clearly attribute to the disease pattern. These findings suggest further 
improvement in the detection of the disease through awareness and education. Further 
explorations of the racial factors influencing the breast cancer characteristics are needed, as 
there may be relevant implications for prevention and treatment planning. 
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Table 1. Patient Characteristics according to ethnicity 
                 
 Characteristic   Black White Coloured  Indian p-value ** 
 Number of patients (%) 
 
129 (55,4) 71 (30,5) 13 (5,5) 20 (8,6) 
  Age at diagnosis, mean (SD) 50,6 (11,8) 63,7 (12,0) 56,6 (9,6) 57,8 (11,0) <0,001 
 Menopause (%)* 
       pre -menopausal 
 
44 (34,4) 7 (10,0) 3 (23,1) 3 (15,0) <0,001 
 post menopausal 
 
77 (60,1) 60 (85,7) 10 (76,9) 17 (85,0) 
  hysterectomy  
 
7 (5,5) 3 (4,3) 0 0 
  missing data 
 
1 1 0 0 
  Highest eduction level completed (%)* 
      Primary school 
 
37 (32,5) 2 (3,0) 2 (15,4) 5 (27,8) <0,001 
 High school 
 
57 (50,0) 44 (65,7) 11 (84,6) 12 (66,7) 
  Tertiary school 
 
20 (17,5) 21 (31,3) 0 1 (5,5) 
  missing data 
 
15 4 0 0 
  Income (%)* 
       None 
 
56 (51,9) 28 (46,7) 10 (83,3) 13 (81,3) <0,001 
 < 5000 ZAR 
 
39 (36,1) 12 (20,0) 1 (8,3) 0 (0) 
  > 5000 ZAR 
 
13 (12,0) 20 (33,3) 1 (8,3) 3 (18,7) 
  missing data  21 11 1 4  
 
        * percentages were calculated without taking the missing data into account 
   ** Chi square tests for differences in non-missing proportions between 4 racial groups 
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Table 2.Tumour Characteristics according to ethnicity 
                  
Characteristic   Black White Coloured  Indian p-value ** 
Tumour size, mm, mean (SD) 32,9 (20,6) 25,4 (19,4) 35,6 (26,1) 23,4 (14,1) < 0,05 
Histology (%)* 
      Ductal  
 
100 (84,0) 53 (82,8) 8 (72,7) 15 (78,9) 0,316 
Lobular 
 
3 (2,5) 6 (9,4) 1 (9,1) 3 (15,8) 
 In situ ductal/lobular 
 
11 (9,2) 5 (7,8) 1 (9,1) 1 (5,3) 
 other types 
 
5 (4,2) 0 1 (9,1) 0 
 missing data 
 
10 7 2 1 
 Pathological stage 
      0 
 
4 (3,5) 4 (6,5) 1 (9,1) 1 (5,5) <0,05 
I 
 
11 (9,7) 10 (16,4) 2 (18,2) 3 (16,7) 
 II 
 
47 (41,6) 33 (54,1) 5 (45,4) 10 (55,5) 
 III 
 
49 (43,4) 14 (23,0) 3 (27,3) 4 (22,2) 
 IV 
 
2 (1,8) 0 (0) 0 (0) 0 (0) 
 missing data 
 
16 10 2 2 
 Tumour grade (%)* 
      1 
 
11 (10,3) 11 (18,3) 0 (0) 3 (15,8) 0,589 
2 
 
56 (52,3) 25 (41,7) 5 (55,5) 10 (52,6) 
 3 
 
40 (37,4) 24 (40,0) 4 (44,4) 6 (31,6) 
 missing data 
 
22 11 4 1 
 Oestrogen receptors 
      positive 
 
88 (75,2) 54 (85,7) 7 (63,6) 16 (84,2) 0,212 
negative 
 
29 (24,8) 9 (14,3) 4 (36,4) 3 (15,8) 
 missing data 
 
12 8 2 1 
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Progesteron receptors 
      positive 
 
68 (58,1) 46 (74,2) 6 (54,5) 12 (63,2) 0,181 
negative 
 
49 (41,8) 16 (25,8) 5 (45,5) 7 (36,8) 
 missing data 
 
12 9 2 1 
 HER 2 
      positive 
 
47 (41,6) 16 (26,7) 1 (9,1) 7 (41,2) 0,058 
negative 
 
66 (58,4) 44 (73,3) 10 (90,9) 10 (58,8) 
 missing data 
 
16 11 2 3 
              
       * percentages were calculated without taking the missing data into account 
  ** Chi square tests for differences in non-missing proportions between 4 racial groups 
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Abstract 
Cervical cancer is the second most common cancer amongst South African women and is 
the leading cause of cancer related deaths in this region. Several international studies on 
radiation-induced DNA damage in lymphocytes of cervical cancer patients remain 
inconclusive. Despite the high incidence of cervical cancer in South Africa, and the extensive 
use of radiotherapy to treat it, there is were no data on the chromosomal radiosensitivity of 
South African cervical cancer patients. Since many of these patients are HIV-positive, the 
effect of HIV infection on chromosomal radiosensitivity was also investigated. Blood 
samples from 35 cervical cancer patients (20 HIV-negative and 15 HIV-positive) and 20 
healthy controls were exposed to in vitro doses of 6MV X-rays of 2 and 4 Gy. Chromosomal 
radiosensitivity was assessed with the micronucleus (MN) assay. MN scores were obtained 
with an automated microscopic system, Metafer 4 platform (Metasystems). Three scoring 
methods used with the MNScore module of Metafer, Metasystems were compared. Cervical 
cancer patients had higher MN values than healthy controls, with HIV-positive patients 
having the highest MN values. Differences between groups were significant when using a 
scoring method that corrects for both false positive and false negative MN. This study 
suggests increased chromosomal radiosensitivity in South African cervical cancer patients. 
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Introduction 
Cervical cancer is the most common cancer amongst women in Sub-Saharan Africa, with an 
age-standardised incidence rate of 34.8 per 105 females (1). Cervical cancer is also the 
leading cause of cancer-related deaths amongst women in this region, with 22.5 per 105 
women dying from the disease annually (1). It is well-established that infection with 
oncogenic Human Papilloma Viruses (HPV) is the main cause of cervical cancer (2, 3). The 
high incidence of cervical cancer in Africa is likely due to a combination of factors. These 
include lack of awareness of the disease and its causes, as well as challenges in 
implementing regular HPV Papanicolaou (Pap)-smear screenings and HPV vaccinations, 
which have only recently been introduced into the South African health care system (4-6) 
While many women are infected with the HPV virus, not all go on to develop cervical cancer 
(7). Heritability studies have shown that there is a genetic link to cervical cancer 
susceptibility (8) and recent reports have shown an association between cervical cancer and 
genes involved in DNA damage repair. These include genes such as APE1, XRCC2, XRCC3, 
ERCC1, ERCC2, ERCC4, ATM (9-12). 
Enhanced chromosomal radiosensitivity is related to defects in genes involved in DNA 
damage repair (13). The first indication for a possible inherited basis for radiosensitivity 
came from patients with rare genetics syndromes such as Ataxia Telangiectasia and 
Nijmegen breakage syndrome (13). These patients were shown to display not only clinical, 
but also in vitro chromosomal radiosensitivity (14). Patients with these syndromes have 
germline mutations in genes involved in DNA damage repair and also displayed 
predisposition to many cancers. Their increased chromosomal radiosensitivity led to studies 
that showed an enhanced in vitro chromosomal radiosensitivity in cancer patients, including 
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breast, head and neck and prostate cancer (15-18). Mutations in DNA repair genes not only 
lead to increased chromosomal radiosensitivity in these patients but may also predispose 
them to the disease (13, 17, 19, 20).  The in vitro chromosomal radiosensitivity of 
lymphocytes of cervical cancer patients has been investigated using a variety of cytogenetic 
assays, however results have been unclear (21-24).   
A well-established method to measure chromosomal radiosensitivity is the Micronucleus 
(MN) assay, which quantifies residual chromosome damage resulting from mis-or non-
repaired double strand breaks after exposure to radiation. This assay can be performed on 
lymphocytes, which are an attractive model for radiosensitivity studies as they are easily 
obtainable through venepuncture. MN scoring in this assay can be automated with an MN 
scoring module for the Metafer 4 platform (MetaSystems, Altlussheim, Germany). The 
MNScore micronucleus software module allows automatic screening of binucleate cells and 
the subsequent scoring of MN in these cells (25) (Schunck et al., 2004). With the system, 
different scoring methods can be utilized that involve varying degrees of visual validation of 
automated scorings to correct for false positive and false negative MN and reject unsuitable 
cells (26, 27). The benefits and challenges of using the MN assay with the Metafer 4 
platform have been documented elsewhere (26-32).  
A study performed by our group (33) has previously shown that individuals infected with 
Human Immunodeficiency Virus (HIV) are more chromosomally radiosensitive than 
uninfected people. In South Africa there are approximately 5.7 million people living with HIV 
(34). HIV, HPV and cervical cancer are epidemiologically associated and in 1993 invasive 
cervical carcinoma was classified as an AIDS-defining illness by the United States Centers for 
Disease Control and Prevention (35). Rates of HPV infection increase with decreasing CD4 
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cell count (36) and studies have shown that HPV infection still persists in a high proportion 
of patients receiving HAART treatment (37). Due to the high rate of HIV in Africa and its 
association with cervical cancer, it is likely that a significant proportion of cervical cancer 
patients seeking treatment will be HIV-positive.  
The aim of this study was to investigate the in vitro chromosomal radiosensitivity in South 
African cervical cancer patients by means of the MN assay using a case-control study design. 
Concurrently, we evaluated different scoring methods when using the MN assay with the 
Metafer 4 platform. Due to the high rate of HIV in South Africa and its association with 
cervical cancer, the effect of HIV on chromosomal radiosensitivity of patients was also 
considered. 
Materials and methods 
Study population: 
Blood samples were obtained via venepuncture from a total of 35 cervical cancer patients 
(mean age 46) and 20 healthy female controls (mean age 41).  15 patients were infected 
with HIV (mean age 43) and 20 were negative for HIV infection (mean age 49). Patients were 
recruited from Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), a public 
hospital in Johannesburg, South Africa, where they were undergoing curative 
hysterectomies or attending a radiotherapy clinic. Information about patients was obtained 
from questionnaires and hospital files. None of the patients had received chemotherapy or 
radiotherapy prior to sample collection. All patients had squamous cell carcinoma tumours.  
The majority of patients had late-stage disease. Only five were early-stage disease and 
disease stage was unknown for one patient. The healthy controls were staff members at 
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CMJAH. All blood donors signed informed consent and the study was approved by the 
Human Research Ethics Committee, University of Witwatersrand, Johannesburg, South 
Africa (M110230). 
Irradiations and Micronucleus assay: 
Lymphocyte cultures were set up by adding 0.5 ml of heparinised blood to 4.5 ml of  Roswell 
Park Memorial Institute 1640 (RPMI) medium (BioWhittaker, Walkersville, USA) in tissue 
culture flasks (25 cm2) that was supplemented with 13% foetal bovine serum (Gibco-
Invitrogen, New York, USA) and antibiotics (50 U/ml penicillin and 50 mg/ml streptomycin; 
Gibco-Invitrogen). The medium was pre-warmed to 37°C and gassed (5%CO2/95% air). The 
radiations were done in the Radiation Oncology Unit at CMJAH. Culture flasks were placed 
in a Phantom-water tank at room temperature and irradiated with X-rays using a 6 MV 
photon beam from a medical linear accelerator (Siemens Healthcare, Erlangen, Germany). 
The distance from the culture flasks to the radiation source was 100 cm at an angle of 90 
degrees. The field size at the depth of the sample was 10X10 cm. Samples were irradiated 
with 2 Gray (Gy) and 4 Gy at a dose rate of approximately 1.33 Gy/min. A 0 Gy dose was 
used as a sham-irradiated control. For each dose point, 2 co-cultures were set up. 
Immediately after irradiation the lymphocytes were stimulated with 100 µl of 
phytohaemagglutinin (stock solution 1mg/ml, Sigma-Aldrich, St Louis, MO, USA) and 23h 
later 20 µl cytochalasin B (stock solution of 1.5mg/ml, Sigma-Aldrich) was added to block 
cytokinesis. Cells were harvested at 70h after stimulation using a cold (4°C) hypotonic shock 
with 7ml 0.075M KCl (Merck, Darmstadt, Germany). This was followed by fixation in 
methanol:acetic acid:Ringer (0.9% NaCl) solution (4:1:5) (Merck) at 4°C overnight. 
Thereafter cells were fixed another three times with methanol:acetic acid (4:1)(Merck). Cell 
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suspensions were dropped on coded slides and stored at 4°C overnight. Slides were 
mounted with vectashield containing DAPI (4,6-diamidino-2-ohenylindole; Vector 
Laboratories, Burlingame, USA) before being scanned automatically with the Metafer 4 (28, 
32). 
Scoring: 
Microscopic analysis was performed with the Metafer 4 platform connected to a motorised 
Zeiss AxioImager M1 microscope. MNScore software module of Metasystems identifies BN 
and displays them in an image gallery with a MN count per cell. Details of how this system 
works have been described previously (28, 32). We used the parameters of the classifier of 
Willems et al. (2010) (32) with minor adjustments. Three different scoring methods can be 
employed involving varying degrees of visual validation of automated scores. The first is the 
‘fully-automated’ scoring method in which MN counts are obtained directly by the MNScore 
module (32). The second is a ‘semi-automated’ scoring method which has been discussed in 
other publications (26, 27, 38). In this study, we referred to this method of scoring as semi-
automated A, where only false positive MN are corrected. As an extra validation, we 
introduced a third scoring method, referred to as semi-automated B. In this method, every 
BN cell (with and without MN) was checked in the image gallery and false negative MN were 
also corrected, in addition to the false positive MN corrected in semi-automated A.  For 
each sample, ‘fully-automated’, ‘semi-automated A’ and ‘semi-automated B’ MN scores 
were obtained by 2 experienced scorers. The average number of BN per data point was 
1600 BN. Data points with less than 500 BN were not included.  All results were normalised 
to a MN frequency in 1000 BN.  
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The nuclear division index (NDI) was also calculated according to the formula: NDI = 
(N1+2N2+3N3+4N4)/ Ntotal, with N1-N4 is the number of cells with 1-4 nuclei and Ntotal 
the total number of cells scored (Ntotal = 500). 
Statistical analysis: 
Statistical analysis was performed with Graphpad Prism 6. Differences between means of 
MN counts in the various groups were tested for significance with the Mann-Whitney test. 
This statistical test was used as it is a non-parametric, distribution-free test that is suitable 
to compare groups with small sizes where no underlying distribution can be assumed. 
Significance was set at p<0.05. 
Results 
MN Values of cervical cancer patients vs healthy controls obtained with 3 scoring methods:  
MN frequencies of cervical cancer patients were compared to healthy controls using the 
three different scoring methods of the Metafer system. Radiation-induced MN yields were 
calculated by subtracting spontaneous MN yields from MN yields in irradiated cells. 
Spontaneous MN values and radiation-induced values for 2 Gy and 4 Gy are listed in Table 1. 
Using the automated and ‘semi-automated A’ scoring method, no significant differences 
were detected between patients and controls. With the ‘semi-automated B’ scoring 
method, patients had clearly higher MN values compared to controls for all radiation dose 
points, the difference between the groups being significant at 2 Gy (p = 0. 0075) and 4 Gy (p 
= 0.0059).  
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MN values of HIV-positive cervical cancer patients compared to HIV-negative cervical cancer 
patients and healthy controls: 
To investigate if HIV has an influence on the chromosomal radiosensitivity of the cervical 
cancer patients, the group of cervical cancer patients was split in HIV-positive and HIV-
negative patients. Based on the results shown in Table 1, to compare HIV-positive and HIV-
negative patients to controls, we used the ‘semi-automated B’ scoring method only. The MN 
values of healthy controls, HIV-positive patients and HIV-negative patients are presented in 
Figure 1.  The HIV-negative patients had clearly higher MN compared to controls but the 
difference was only significant at 4 Gy (p = 0.037). For 2 Gy, there was no significant 
difference between HIV-negative cancer patients and controls (p = 0.060), however there 
was a clear shift towards higher MN values for the patients (figure 1).  
In HIV-positive patients at 4 Gy there were 2 samples with insufficient BN and were thus 
excluded from the analysis. Although not statistically significant, the HIV-positive patients 
had higher MN values than the HIV-patients. The HIV-positive patients had statistically 
significant higher radiation induced MN values than healthy controls at both 2 Gy (p = 0.006) 
and 4 Gy (p = 0.008).  
Nuclear division index (NDI) of cervical cancer patients and healthy controls: 
To evaluate the quality of the MN assay in the different groups, we calculated the nuclear 
division index. The healthy controls had NDI for 0, 2 and 4 Gy of respectively 2.170; 2.073 
and 1.668, while the cancer patients had NDI for 0, 2 and 4 Gy of respectively 2.117; 1.883 
and 1.535. The differences in NDI were statistically different between both groups for the 2 
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and 4 Gy (p = 0.0091 and p = 0.0182). The HIV-positive cancer patients had the lowest 
ranges of NDI. 
Discussion  
The aim of this study was to compare the chromosomal radiosensitivity of South African 
cervical cancer patients with healthy controls using the micronucleus assay. The 
development of the MNScore software module by Metasystem has allowed the automation 
of MN scoring (25). The system has been documented in several studies on biodosimetry 
and cancer research and allows for different scoring methods that involve varying degrees 
of visual validation of automated scores (26-32). The presence of apoptotic nuclei and a 
wide cell size range have been mentioned as factors impairing the efficiency of the Metafer 
system (26, 29). Another challenge noted is that the system “may fail to identify all MN if 
they are close or attached to the main nuclei or if there are more than one MN in the same 
BN cell” (29). The cancer population group in this study was of late-stage disease, which can 
contribute to apoptotic and varying cell sizes and the in vitro doses we administered can 
result in multiple MN. For these reasons we included a ‘semi-automated B’ scoring method 
as an extra validation step to correct for false positive and false negative MN in all BN 
detected. While ‘semi-automated B’ scoring on the Metafer does take longer than ‘semi-
automated A’ scoring, it is still quicker than scoring manually under a microscope. The 
system also adds additional benefits in that the BN screening is less subjective and the full 
image gallery can be archived as a ‘virtual slide’ that can be re-analysed whenever 
necessary. The Metafer has been used in two similar population studies on breast and 
prostate cancer populations (30, 31). Using the automated scores only, Varga et al.  (30, 31) 
were able to distinguish clearly between breast cancer patients and controls but not 
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prostate cancer patients and controls. The Metafer scoring has not previously been used to 
investigate a cervical cancer population. When comparing cervical cancer patients to 
controls using the ‘fully-automated’ and ‘semi-automated A’ method, no differences were 
seen between patients and controls (Table 1). With the ‘semi-automated B’ method, 
patients had significantly higher MN at 2 and 4 Gy. At the 4 Gy dose, many BN have multiple 
MN which will be missed in the ‘fully-automatic’ and ‘semi-automatic A’ scoring methods. 
Another reason is the high level of cell debri that was noted on the slides of the cancer 
patients, which may be a result of increased apoptosis, due to elevated radiosensitivity or 
other cellular stress associated with late-stage disease. The lower yield of BN in the cancer 
group, which also may be a results of apoptosis or cellular stress, was reflected in the 
significantly lower NDI compared to the healthy control group. These issues can result in a 
number of false positive MN that can affect the automated scoring. 
Our results suggest increased chromosomal radiosensitivity in patients compared to 
controls. Previous studies on the chromosomal radiosensitivity of lymphocytes of cervical 
cancer patients have been inconclusive. In a study by Ban et al. (22), using the micronucleus 
assay, patients were found to have lower MN frequencies than controls. Blood samples, 
however, were taken in a large proportion of the patients after or during radiotherapy 
treatment. This resulted in high spontaneous MN values which affect radiation induced 
values. It was also suggested by the authors that the lower MN values seen in cervical 
patients may be the result of “an adaptive-response like phenomenon” from the in vivo 
therapy. A similar study to ours was performed by Encheva et al. (39), where MN values 
from lymphocytes of 40 gynaecological patients (23 cervical and 17 endometrial combined 
into one group) were compared to 10 healthy controls. They found similar MN values for 
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the combined gynaecological patients and the controls after exposure to an in vitro dose of 
1.5 Gy. The inclusion of 17 patients with endometrial cancer makes it difficult to draw 
conclusions on the chromosomal radiosensitivity of cervical cancer patients alone.  Our 
study was conducted on a cohort with late-stage disease and unique genetic background.  
It is now accepted that inherited genes play a role in cervical cancer susceptibility as only a 
fraction of women with HPV infection progress to disease, and the disease shows familial 
clustering (40). HPV-induced cervical carcinogenesis is a complex, multi-faceted process that 
is not yet well understood (7). While many studies on cervical cancer have focused on genes 
involved in immune response (41-43), genes involved in DNA damage repair and cervical 
cancer are also an area of interest. Recent reports have shown associations with genes 
involved in DNA damage repair and cervical cancer risk (9-12, 44). Additionally, studies have 
shown Fanconi Anemia (FA) patients (patients with deficient DNA damage repair 
mechanisms) to be more susceptible to HPV-positive head and neck squamous cell 
carcinomas compared to non-FA patients with the same lesions (45). Park et al. (46) showed 
that there is an interplay between HPV and the FA pathway.  Defects in DNA damage 
processing genes affect chromosomal radiosensitivity. The increased chromosomal 
radiosensitivity observed in our study suggests deficient DNA damage processing, which 
may play a role in increased susceptibility to cervical cancer. The exact role of DNA damage 
repair genes and cervical cancer is still unclear. Evidence from retroviruses show that when 
a virus integrates into the host genome, a double strand break is formed, causing a DNA 
damage response similar to that seen when cells are exposed to ionising radiation (47). If 
these DSB are not repaired and the integration process is not properly regulated, it can 
result in genomic instability which can lead to carcinogenesis (12). Research has also shown 
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that HPV’s preferential targets of integration are fragile sites (48). DNA damage repair genes 
like ATR, BRCA1, CHK1, have been shown to play a role in fragile site stability and expression 
(49-52). There may be a link between compromised DNA damage repair, fragile sites 
stability and susceptibility to HPV integration and subsequent carcinogenesis. 
Our research group previously showed HIV-positive individuals to be more radiosensitive 
than non-infected individuals (33). HIV is widespread in Africa and the epidemiological link 
between HIV and cervical cancer means that many women seeking treatment (often 
radiotherapy) for the disease will be HIV-positive. For this reason, we added a group of HIV-
positive cervical cancer patients to our cohort. In 2 HIV-positive patients, we couldn’t obtain 
enough BN after the 4 Gy dose. This is likely due to HIV infection which compromises CD4 
counts, in combination with the late-stage disease causing cells to not withstand the 
cytotoxicity of a dose as high as 4 Gy.  HIV-positive cervical cancer patients had higher MN 
values than HIV-negative cervical cancer patients, despite the difference not being 
significant (figure 1). This could suggest an additional effect of HIV on the radiosensitivity of 
cervical cancer patients that are infected with HIV. The HIV-positive patients had MN values 
that were significantly higher than the healthy controls at 2 Gy and 4 Gy. This confirms the 
results of Baeyens et al. (33).  
Our results show when using the Metafer system on cancer populations with advanced 
disease or HIV, the ‘semi-automated B’ scoring method yields the most reliable results. This 
technique seems to be useful to investigate the radiosensitivity of other cancer population 
groups. Our results also showed cervical cancer patients to have higher MN values than 
controls, suggesting increased chromosomal radiosensitivity.  Our findings confirm that 
cervical cancer patients seeking radiotherapy who are HIV-positive may form a distinct 
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group that require individualized treatments. It would be interesting to follow up the in vitro 
data with the clinical response of HIV cervical cancer patients undergoing radiotherapy. 
Evidence suggests that these patients suffer from increased radiation side-effects but 
further investigation is required to confirm this (53-55). Our results highlight that when 
doing studies in developing countries, factors like HIV should be considered. Further studies 
are needed to unravel the link between chromosomal radiosensitivity, DNA damage repair 
genes and the underlying mechanisms of susceptibility to HPV-induced carcinogenesis. 
These could lead to a marker for increased cancer risk in women with HPV infections and 
could assist in prioritizing those needing regular pap-smears which is helpful in resource-
limited countries such as South Africa.  
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Table 1: Summary of spontaneous and radiation - induced MN values for controls and cervical cancer patients with 3 scoring 
methods. *Significantly different from controls (Mann-Whitney test p<0.05) 
                
 
AUTOMATED   SEMI-AUTOMATED A   SEMI-AUTOMATED B 
 
 
  0Gy 2Gy 4Gy     0Gy 2Gy 4Gy     0Gy 2Gy 4Gy 
 
CONTROLS 
N 20 20 20   N 20 20 20   N 20 20 20 
 MEAN 56 125 323 
 
MEAN 10 115 317 
 
MEAN 13 155 454 
 SEM 8 8 13   SEM 1 5 11   SEM 1 6 9 
 
PATIENTS 
N 35 35 35   N 35 35 35   N 35 35 33 
 MEAN 66 144 320 
 
MEAN 12 124 327 
 
MEAN 14 *179 *506 
 SEM 7 9 14   SEM 1 4 10   SEM 1 5 12 
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Figure 1: Radiation – induced MN yields after 2 Gy and 4Gy irradiations for cancer patients and 
controls. Midline = mean MN yield of the group. * Significantly different from controls (p<0.05) 
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8 APPENDIX B: Ethical clearance certificates, informed consents and questionnaires 
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Study title: Analysis of in vitro chromosomal radiosensitivity and underlying mechanisms of 
DNA repair in South African women with breast cancer 
Investigators: Dr A Baeyens, O Herd, X Muller 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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INFORMED CONSENT FORM 
Good Day, 
We are Dr. A. Baeyens and students Olivia and Xanthene from the Radiobiology research unit of the 
Department of Radiation Sciences, WITS medical School. We are part of a collaborative study 
between WITS University and iThemba LABS to investigate the radiosensitivity of breast cancer 
patients. Information on individual radiosensitivity helps to monitor the radiotherapy treatments. 
We invite you to consider participating in a research study. Your participation in this study is entirely 
voluntary. If you decide to take part in this study, you will be asked to sign this document to confirm 
that you understand the study. You will be given a copy to keep.  
Should you decide not to participate in the study or if you agree and then change your mind, there 
will be no implications for you and the best treatment available for you will still be given. 
If you agree to participate, we kindly ask you to donate 20ml of blood once. This is not a lot of blood; 
it is only 4 teaspoons and will not harm you. We will use your blood sample to test the sensitivity to 
radiation. We also kindly ask you if we can use a part of your tumour tissue that will be removed by 
the surgeon during your breast operation. This part of tumour tissue we want to use to investigate if 
there is a link between the radiosensitivity seen in blood and in the tumour. Both your blood sample 
and tissue sample will be used to unravel the underlying mechanism of radiosensitivity. We also ask 
permission to view your medical files if we need to obtain any further medical information that may 
be relevant to our study.  
There is no direct benefit to you. But your participation in this study will contribute to the 
development of greater knowledge of radiosensitivity and may help to ameliorate the radiotherapy 
treatments of breast cancer patients. 
The research is completely confidential, which means that your name will not be recorded on any of 
our laboratory information. The consent forms will be locked away and only accessible by the 
researchers. We will require some personal details from you (your age, language, monthly income, 
do you have children, see questionnaire attached) and we also want to know if you are a smoker or 
if you have any other major illness, as this can have an influence on our tests. 
You are free to ask any questions about this study and discuss any worries you may have with the 
research staff. 
Thank you very much for your time 
Regards, 
Dr A. Baeyens, Olivia Herd and Xanthene Muller 
 
Study title: Analysis of in vitro chromosomal radiosensitivity and underlying mechanisms of 
DNA repair in South African women with breast cancer 
Investigators: Dr A Baeyens, O Herd, X Muller 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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Study participant number:                                                                         Date of Birth: 
Contact no: 
INFORMED CONSENT: 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
radiosensitivity of breast cancer patients 
I have also received, read and understood the above written information regarding this study 
I have no further questions and declare myself prepared to participate in the study. 
 
PARTICIPANT: 
Name (Print): 
 
Signature and date: 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
Name (Print): 
 
Signature and date: 
 
WITNESS (IF APPLICABLE): 
Name (Print): 
 
Signature and date: 
  
Study title: Analysis of in vitro chromosomal radiosensitivity and underlying mechanisms of 
DNA repair in South African women with breast cancer 
Investigators: Dr A Baeyens, O Herd, X Muller 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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RADIOSENSITIVITY STUDY ON BREAST CANCER PATIENTS 
QUESTIONNAIRE FOR PARTICIPANTS 
 
Age: ........................................................................................................................................... 
Home language:......................................................................................................................... 
Ethnic group:.............................................................................................................................. 
Place of Birth:............................................................................................................................. 
What is your monthly income? - None 
     - less than R500 
- between R500 and R1000 
- between R1000 and R2000 
- between R2000 and R5000 
- more than R5000 
- unknown 
 
Do you have children?how many?............................................................................................ 
What is your highest grade completed? -     Primary school 
- High school 
- Tertiary school 
Have you ever smoked?/ do you currently smoke?................................................................... 
Do you have any other major illness?........................................................................................ 
Do you know your HIV status?................................................................................................... 
Will you disclose your status to me?are you positive or negative?........................................... 
Do you still have monthly bleed (period)?................................................................................ 
Participant questionnaire     Participant initials: 
        Study participant number: 
 
Study title: Analysis of radiosensitivity in South African cervical cancer patients 
Investigators: Dr A Baeyens, O Herd 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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INFORMED CONSENT FORM (patients) 
Good Day, 
We are Dr. A. Baeyens and Olivia Herd from the Radiobiology research unit, Department of Radiation 
Sciences and NRF- iThemba LABS based at Charlotte Maxeke Johannesburg Academic Hospital, 
Orange block, 4th floor. We are part of a collaborative study between WITS University and NRF - 
iThemba LABS to investigate the radiosensitivity of cervical cancer patients. Information on 
individual radiosensitivity helps to monitor the radiotherapy treatments. 
We invite you to consider participating in a research study. Your participation in this study is entirely 
voluntary. If you decide to take part in this study, you will be asked to sign this document to confirm 
that you understand the study. You will be given a copy to keep.  
Should you decide not to participate in the study or if you agree and then change your mind, there 
will be no implications for you and the best treatment available for you will still be given. 
If you agree to participate, we kindly ask you to donate 5ml of blood once. This is not a lot of blood; 
it is only 1 teaspoon and will not harm you. We will use your blood sample to test the sensitivity to 
radiation. We also kindly ask you if we can use a part of your cervical tissue (exfoliated cells) and 
tumour (biopsy) that will be taken while the doctor is taking samples for routine tests. This may 
cause you added discomfort. These samples will be used to investigate if there is a link between the 
radiosensitivity seen in blood and in cervical cells. Both your blood sample and tissue samples will be 
used to unravel the underlying mechanism of radiosensitivity. We also ask permission to view your 
medical files if we need to obtain any further medical information that may be relevant to our study.  
There is no direct benefit to you. But your participation in this study will contribute to the 
development of greater knowledge of radiosensitivity and may help to further develop the 
radiotherapy treatments of cervical cancer patients. 
The research is completely confidential, which means that your name will not be recorded on any of 
our laboratory information. The consent forms will be locked away and only accessible by the 
researchers. We will require some personal details from you (your age, language, monthly income, 
see questionnaire attached) and we also want to know if you are a smoker or if you have any other 
major illness, as this can have an influence on our tests. 
You are free to ask any questions about this study and discuss any worries you may have with the 
research staff. 
Thank you very much for your time. 
Regards, 
 Dr A. Baeyens and Olivia Herd 
Study title: Analysis of radiosensitivity in South African cervical cancer patients 
Investigators: Dr A Baeyens, O Herd 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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INFORMED CONSENT FORM (controls) 
Good Day, 
We are Dr. A. Baeyens and Olivia Herd from the Radiobiology research unit, Department of Radiation 
Sciences and iThemba LABS based at Charlotte Maxeke Johannesburg Academic Hospital, Orange 
block, 4th floor. We are part of a collaborative study between WITS University and NRF - iThemba 
LABS to investigate the radiosensitivity of cervical cancer patients. Information on individual 
radiosensitivity helps to monitor the radiotherapy treatments. 
We need healthy individuals as a control group for our study. Therefore we invite you to consider 
participating in a research study. Your participation in this study is entirely voluntary. If you decide to 
take part in this study, you will be asked to sign this document to confirm that you understand the 
study. You will be given a copy to keep.  
If you agree to participate, we kindly ask you to donate 5ml of blood once. This is not a lot of blood; 
it is only 1 teaspoon and will not harm you. We also kindly ask for some left-over cells from your 
cervical smear that is being done by the doctor for routine tests. This will not give you extra 
discomfort. We will use these samples to test the sensitivity to radiation. We also ask permission to 
view your medical files if we need to obtain any further medical information that may be relevant to 
our study. 
There is no direct benefit for you. But your participation in this study will contribute to the 
development of greater knowledge of radiosensitivity and help to further develop the radiotherapy 
treatments of cervical cancer patients. 
The research is completely confidential, which means that your name will not be recorded on any of 
our laboratory information. The consent forms will be locked away and only accessible by the 
researchers. We will require some personal details from you (your age, language, monthly income, 
see questionnaire attached) and we also want to know if you are a smoker or if you have any other 
major illness, as this can have an influence on our tests. 
You are free to ask any questions about this study and discuss any worries you may have with the 
research staff. 
Thank you very much for your time 
Regards, 
Dr A. Baeyens and Olivia Herd 
 
 
Study title: Analysis of radiosensitivity in South African cervical cancer patients 
Investigators: Dr A Baeyens, O Herd 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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Study participant number:                                                                         Date of Birth: 
Contact no: 
INFORMED CONSENT: 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
radiosensitivity of cervical cancer patients 
I have also received, read and understood the above written information regarding this study 
I have no further questions and declare myself prepared to participate in the study. 
 
PARTICIPANT: 
 
Name (Print): 
 
Signature and date: 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
Name (Print): 
 
Signature and date: 
 
WITNESS (IF APPLICABLE): 
 
Name (Print): 
 
Signature and date: 
Study title: Analysis of radiosensitivity in South African cervical cancer patients 
Investigators: Dr A Baeyens, O Herd 
Institution: WITS University and iThemba LABS 
Contact numbers: Dr A Baeyens: 072 919 8872   Olivia Herd: 082 778 4929 
                                Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
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ANALYSIS OF RADIOSENSITIVITY ON CERVICAL CANCER PATIENTS 
QUESTIONNAIRE FOR PARTICIPANTS 
 
Age: ........................................................................................................................................... 
Home language:......................................................................................................................... 
Race:.......................................................................................................................................... 
Place of Birth:............................................................................................................................. 
What is your monthly income? - None 
     - less than R500 
- between R500 and R1000 
- between R1000 and R2000 
- between R2000 and R5000 
- more than R5000 
- unknown 
 
What is your highest grade completed? -     Primary school 
- High school 
- Tertiary school 
Have you ever smoked?/ do you currently smoke?................................................................... 
Do you have any other major illness?........................................................................................ 
Do you know your HIV status?................................................................................................... 
Will you disclose your status to me? are you positive or negative?........................................... 
 
 
Participant questionnaire     Participant initials: 
Study participant number:
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9 APPENDIX C: Detailed protocols 
9.1 MN assay on lymphocytes 
Heparinised blood (0.5 ml) was added to 4.5 ml complete medium (Appendix D) pre-
warmed to 37°C and gassed (5%CO2/95% air). Culture flasks were placed in a phantom-
water tank at room temperature (RT) and irradiated with 6 MV X-rays. The distance from 
the culture flasks to the radiation source was 100 cm at an angle of 90 degrees. The field 
size at the depth of the sample was 10X10 cm. Once irradiated, lymphocytes were 
stimulated into division by adding 100 µl stock solution phytohaemagglutinin (Sigma-
Aldrich) (Appendix D). After 23 hrs in culture 20 µl stock solution of cytochalasin B (Sigma-
Aldrich) (Appendix D) was added to block cytokinesis. 70 hrs post-stimulation, cells were 
harvested by adding a cold (4°C) hypotonic shock of 7 ml 0.075M KCl (Merck) (Appendix D), 
followed by fixation in 4:1:5 methanol:acetic acid:Ringer solution (Merck) (Appendix D) at 
4°C overnight. Cells were subsequently fixed 3 X in methanol:acetic acid (4:1). Cell 
suspensions were dropped onto coded slides and slides were mounted with vectashield 
containing DAPI (Vector Laboratories) before being scanned automatically with the Metafer 
4 platform. 
9.2 Lymphocyte extraction for γ-H2AX assay 
The blood was left to stand in EDTA tubes for 30 mins at RT. Blood was diluted (1:1) with 
RPMI 1640 (BioWhittaker) and slowly poured at a 45 degree angle onto Histopaque-1077 
(Sigma-Aldrich), a solution of polysucrose and sodium diatrizoate that creates a density 
gradient upon centrifugation and separates white blood cells from red blood cells and 
plasma. Tubes were centrifuged (slow start/stop) at 1500 rpm for 15 mins to set up the 
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density gradient. The lymphocyte layer was transferred to a clean tube and washed 3 X with 
5 ml complete medium (Appendix D). Cells were counted with trypan blue (Sigma-Aldrich) 
staining and a haemocytometer. 0.8 X 106 cells were planted in 2 ml complete medium. 
9.3 γ-H2AX immunostaining 
After overnight fixation in 0.5% PFA (Appendix D), slides were washed in 1 X Phosphate 
Buffer Saline (PBS) (Appendix D) for 5 mins at RT. Cells were covered with ice-cold 0.2% 
Triton X-100 (Sigma-Aldrich) (Appendix D) at RT in a humidity chamber for 10 mins to 
increase permeability of membranes. Thereafter, slides were washed 3 X in PBS buffer with 
1% Bovine Serum Albumin (BSA) (Roche Diagnostics, Basel, Switzerland) (Appendix D) at RT 
for 10 mins. Cells were incubated for 1 hr in a humidity chamber at RT with primary mouse-
anti-H2AX (1/500 in 1% BSA PBS) (Biolegend, San Diego, USA). This was followed by washing 
3 X in 1% BSA PBS at RT for 10 mins. Cells were incubated for 1 hr at RT with secondary 
antibody, RAM-TRITC (1/1000 in 1% BSA PBS) (Dako, Glostrup, Germany) followed by 
washing 3 X in PBS at RT for 10 mins. Cells were counterstained with DAPI stock solution 
(Sigma-Aldrich) (Appendix D) dissolved in Fluoromount mounting medium (1/500) (Sigma-
Aldrich). 
9.4 Immunohistochemistry to characterize cell cultures 
5-μm sections were cut from FFPE tissues with a microtome. Sections were deparaffinised 
with Toluene (Merck) and rehydrated in ethanol (Merck).  Deparaffinised tissue sections 
were boiled in 1mM citrate acid buffer (Appendix D) for 2 X 5 mins in a microwave oven. 
Citric acid enables antibodies to reach antigens more easily by breaking down formaldehyde 
groups in FFPE. 3% Hydrogen Peroxide (Merck) (Appendix D) was added to tissue sections 
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for 10 mins at RT to remove excess peroxidise that occurs naturally in tissue. The sections 
were incubated with blocking serum for 30 mins at RT. Blocking serum (Appendix D) 
contains 5% normal rabbit serum (stops non-specific binding of rabbit antibody) (Dako); 1% 
BSA (loosely binds to antigens to stop non-specific binding); and 0.2% Tween (increases 
membrane permeability) (Merck). Sections were incubated for 2 hrs at RT with primary Anti-
pan Cytokeratin Antibody AE1+AE3 (1/200 in dilution buffer- Appendix D). Sections were 
washed with PBS (Appendix D) for 2 X 5 mins, followed by a 30 mins incubation at RT with 
biotinylated rabbit anti-mouse secondary antibody (1/200 in dilution buffer) (Dako).  The 
final incubation was for 30 mins at RT with horseradish streptavidin labeled with peroxidase 
(1/200 in dilution buffer) (Dako), followed by treatment with enzyme substrate 3’3 
Diaminobenzidine tetrahydrochloride (Sigma-Aldrich) which reacts with peroxidase and 
forms a visible colour stain. Negative control sections were treated in the same way except 
that they were incubated with dilution buffer instead of primary antibody.  The sections 
were counterstained with Haematoxyline Von Mayer (Merck) and viewed under a light 
microscope.  
9.5 DNA extractions for HPV typing 
9.5.1 Fresh tissue 
DNA was extracted from fresh tissue biopsies using a QIAamp DNA Mini Kit (Qiagen, Venlo, 
Netherlands), according to manufacturer instructions. Approximately 25 mg tissue was 
minced and placed in a 1.5 ml microcentrifuge tube with 180 µl tissue lysis Buffer ATL.  
Specimens were incubated with 20 µl proteinase K (included in kit) in Buffer ATL at 56°C for 
1-3 hrs until tissue lysis. Post tissue lysis, 200 µl cell lysis Buffer AL was added to tubes and 
specimens were incubated at 70°C for 10 mins. 200 µl 100% ethanol (Merck) was added to 
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the tubes to precipitate DNA, followed by vortexing. The mixture was added to a QIAamp 
Mini spin column, centrifuged for 1 min at 8000 rpm. Columns were washed by adding 500 
µl Buffer AW1 followed by centrifugation for 1 min at 8000 rpm. For a second wash, 500 µl 
Buffer AW2 was added to the spin column followed by centrifugation for 1 min at 8000 rpm.  
Columns were spun for another 1 min at 8000 rpm to remove any residual buffer. To elute 
DNA, the spin column was placed into a clean microcentrifuge tube and 200 µl elution 
buffer AE was added. After a 5 mins incubation at RT (optimal time for increased DNA yield), 
tubes were centrifuged for 1 min at 8000 rpm.  
9.5.2 FFPE 
For FFPE, DNA was extracted using the phenol-chloroform method. Sections were warmed 
at 60°C for 2 hrs to soften the paraffin. Sections were washed with xylene (Merck) by adding 
1 ml xylene, placing on a plate shaker for 5 mins, spinning for 3 mins at 12000 rpm and 
removing supernatant. This was repeated 3-5 X until all paraffin was dissolved and removed. 
The pellet was washed with 1 ml 100% ethanol, spun for 2 mins at 12000 rpm and the 
supernatant removed. Pellets were incubated overnight in 1 ml sodium thiocyanate (Merck) 
at 40°C to break crosslinks formed by formaldehyde. The following day, sodium thiocynate 
was removed and pellets were incubated for 2 hrs at 56°C in 400 µl tissue lysis buffer 
(Appendix D) with 40 µl proteinase K (10 mg/ml) (Roche Diagnostics) (Appendix D). After the 
lysis step, samples were incubated for 10 mins at 80°C to inactivate proteinase K. Equal 
amounts of phenol (Sigma Aldrich) and chloroform (Sigma Aldrich) (450 µl each) were added 
to samples which were vortexed and spun for 3 mins at 12000 rpm. The supernatant was 
transferred to a new tube and equal amounts of phenol and chloroform were added (200 µl 
each) followed by vortexing and spinning for 3 mins at 12000 rpm. The supernatant was 
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transferred to a clean tube and 400 µl chloroform was added followed by vortexing and 
spinning for 3 mins at 12000 rpm. The supernatant, containing DNA, was transferred to a 
clean tube and DNA was precipitated by adding 2.5X ice cold 100% ethanol, 3M sodium 
acetate (1/10 volume supernatant) (Appendix D) and placing at -70°C overnight. DNA was 
pelleted by spinning for 30 mins at 12000 rpm (at 4°C) and washed by adding 500 µl ice cold 
70% ethanol, followed by spinning for 10 mins at 12000 rpm (4°C). The ethanol was poured 
off, the pellet dried on the benchtop for 15-30 mins and DNA was dissolved in 50 µl 1XTE 
buffer (Appendix D). 
9.6 Agarose gel electrophoresis for HPV typing 
PCR products for HPV genotyping were separated by 2% agarose gel. 1 g Agarose powder 
(Merck) was dissolved in 50 ml 1X TBE buffer (Appendix D). The gel was left to set at RT in a 
gel-cast after adding 1 µl of GelRed (10,000X stock solution) (Biotium). PCR products (5 µl) 
mixed with 1 µl 1X loading dye (6X stock solution diluted 1:6 in dH2O) (Thermo Scientific) 
were loaded into well and run at 80-100 Volts for 40 mins. A molecular marker of 0.1 to 1.5 
kb (in 0.1kb intervals) (Thermo Scientific) was run concurrently to samples. 
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10 APPENDIX D: Recipes 
Acridine orange stock solution      
(1 mg/ml) 
0.1 g Acridine orange powder 
 
100 ml dH20 
 
  
Acridine orange working solution 
(10 µg/ml) 
0.4 ml Acridine stock solution 
 
40 ml Acridine orange buffer 
   
   Agarose gel 2% (50 ml) 1 g Agarose powder 
  
made to 50 ml with 1X TBE 
  
microwave, add 1 µl GelRed and into cast to set 
   Blocking Serum 0.1 g Bovine serum albumin 
 
0.5 ml Rabbit serum (normal) 
 
200 µl Tween 10 % 
 
10 ml 1X PBS 
   Citric acid buffer (1 mM) (1 L) 0.2 g Citric acid 
  
made up to 1 L with dH2O, pH 6.0 
   Collagenase alone (1 mg/ml) 1 mg Collagenase 
 
1 ml dH20 
   Collagenase/Dispase stock solution 
(100 mg/ml) 
100 mg Collagenase/Dispase lyophilizate 
 
1 ml dH20 
  
 
Collagenase/Dispase working 
solution (1 mg/ml) (1 ml) 
10 µl  working solution (100 mg/ml) 
 990 µl  1X PBS 
   
Collection Medium (100 ml) 500 µl Gentamycin (50 µg/ml) 
 2.5 ml Penicillin/Streptomycin (250 U/ml and 0.25 mg/ml) 
 97 ml DMEM/F12 
   
Complete medium (28.75 ml) 3.75 ml Foetal bovine serum 
 25 ml RPMI 1640 with 50 U/ml penicillin and 50 mg/ml 
streptomycin  
 
  
Culture-initiation medium (100 ml) 1 ml L-Glutamine (2mM) 
 1 ml Penicillin/Streptomycin (100 U/ml and 0.1 mg/ml) 
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 10 ml Foetal bovine Serum 
 90 ml DMEM/F12 
 
  
Cytochalasin B (stock solution 1.5 
mg/ml) 
5 mg Cytochalasin B 
 3.3 ml  Dimethyl sulphoxide (DMSO) 
  
 
DAPI stock solution (0.1 mg/ml) 0.1 mg DAPI powder 
 
1 ml dH20 
   Dilution buffer for IHC 1 ml Blocking serum 
 
9 ml 1X PBS 
   EDTA 0.5M 146.1 g EDTA disodium salt 
  
made up to 1 L with dH2O, pH 8 
   Erythrocyte lysis buffer (500 ml)  0.019 g EDTA (0.5M) 
 
0.5 g KHCO3 
 
4.1 g  NH4Cl 
  
Made up to 500 ml with dH20 
   Hydrogen Peroxide (10 ml) 3% 1 ml  30% Hydrogen peroxide 
 
9 ml 1X PBS 
   KCl 0.075M 5.6 g KCl 
  
made up to 1 L with dH2O 
   Phosphate Buffer Saline 1X (PBS) 
(1 L) 
7.2 g NaCl 
 
0.42 g KH2PO4 
 
1.78 g  Na2HPO4 
 
 made up to 1 L with dH2O, pH 7.2 
   PBS 1% BSA (100 ml) 1 g BSA 
 
100 ml 1X PBS 
   Paraformaldehyde 8% (PFA) 80 g Paraformaldehyde powder 
  
Dissolved at 40°C with drops of 5M NaOH until 
dissolved, pH7.4 
  
made up to 1 L with dH2O 
   Paraformaldehyde 3% 25 ml 8% PFA 
 
41 ml 1X PBS 
   
 
 
145 
 
 
 
 
Paraformaldehyde 0.5% 10 ml  3% PFA 
 
50 ml  1X PBS 
   Phytohaemagglutinin (stock 
solution 1 mg/ml) 
25 mg Phytohaemagglutinin 
 25 ml Sabax injection H2O 
   Poly-L-Lysine solution 0.1w/v (10 
ml) + coating: 
1 ml  Poly-L-Lysine 
 
9 ml dH2O 
  
Added to wells and incubated at 37°C for 1 hr 
  
Wells washed 5X and dried in incubator overnight 
   Proteinase K (10 mg/ml) (1 ml) 10 mg proteinase K 
 
1 ml dH2O 
   Ringer solution (1 L) 0.24 g CaCl2 
 
0.42 g KCl 
 
9 g NaCl 
  
made up to 1 L with dH2O 
   TBE buffer 5X (1 L) 20 ml 0.5M EDTA 
 
24.5 g Boric acid 
 
54 g Tris Base 
  
made up to 1 L with dH2O 
   TE buffer 1X  (100 ml) 0.02 ml 0.5M EDTA 
 
0.012 g Tris base 
 
100 ml dH2O 
   Tissue lysis buffer (250 ml) 0.5 ml 0.5M EDTA 
 
25 ml Tris-HCl 
 
1.25 ml Tween (100%) 
   Triton-100 0.2% (1 ml) 2 µl Triton-100 
 
998 µl 1X PBS 
   Tween 10% (100 ml) 10 ml Tween 
 
90 ml dH2O 
 
 
146 
 
11 APPENDIX E: Chemicals and consumables 
3’3 Diaminobenzidine tetrahydrochloride Sigma-Aldrich, St Louis, MO, USA 
4,6-diamidino-2-phenylindole (DAPI powder) Sigma-Aldrich, St Louis, MO, USA 
70 µm Falcon mesh strainer  BD Biosciences, New Jersey, USA 
6X loading dye Thermo Scientific, Massachusetts, USA 
6-well CellBind® (Corning) plates Corning Incorporated Life Sciences, 
Massachusetts, USA 24 well plates Grenier Bio-one, Monroe, North 
Carolina, USA Acetic Acid Merck, Darmstadt, Germany 
Acridine orange Sigma-Aldrich, St Louis, MO, USA 
Agarose Merck, Darmstadt, Germany 
Anti-pan Cytokeratin Antibody AE1+AE3 Abcam, Cambridge, England, United 
Kingdom Anti-phospho-histone H2AX anti-mouse 
primary antibody 
Biolegend, San Diego, USA 
Biotinylated rabbit anti-mouse secondary 
antibody  
Dako, Glostrup, Denmark 
Bovine Serum Albumin  (BSA) Roche Diagnostics, Basel, Switzerland 
Chloroform  Sigma-Aldrich, St Louis, MO, USA 
Citrate acid buffer  Merck, Darmstadt, Germany 
Collagenase Sigma-Aldrich, St Louis, MO, USA 
Collagenase/Dispase  Roche Diagnostics, Basel, Switzerland  
Culture flasks 25cm2 Grenier Bio-one, Monroe, North 
Carolina, USA Cytochalasin B Sigma-Aldrich, St Louis, MO, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St Louis, MO, USA 
Distilled H2O Merck, Darmstadt, Germany 
DMEM/F12  BioWhittaker, Walkersville, USA 
Ethanol  Merck, Darmstadt, Germany 
Ethylene-diamine-tetra-acetate (EDTA) Merck, Darmstadt, Germany 
Fluoromount mounting medium  Sigma-Aldrich, St Louis, MO, USA 
Foetal Bovine Serum (FBS) Gibco-Invitrogen, New York, USA 
GelRed Biotium, California, USA 
Gentamycin BioWhittaker, Walkersville, USA 
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Haematoxyline Von Mayer Merck, Darmstadt, Germany 
Histopaque-1077  Sigma-Aldrich, St Louis, MO, USA 
Horseradish Streptavidin Peroxidase Dako, Glostrup, Denmark 
Hydrogen Chloride (HCl) 1M Merck, Darmstadt, Germany 
Hydrogen Peroxide  Merck, Darmstadt, Germany 
Keratinocyte Growth Medium (KGM) Lonza, Basel, Switzerland 
L-Glutamine  Lonza, Basel, Switzerland 
Liberase Research Grade Purified Enzyme Blend Roche Diagnostics, Basel, Switzerland  
Methanol Merck, Darmstadt, Germany 
Molecular marker Thermo Scientific, Massachusetts, USA 
Paraformaldehyde Merck, Darmstadt, Germany 
Penicillin/Streptomycin Gibco-Invitrogen, New York, USA 
Phenol Sigma-Aldrich, St Louis, MO, USA 
Poly-L-Lysine  Sigma-Aldrich, St Louis, MO, USA 
Poly-L-Lysine-coated slides Thermo Scientific, Massachusetts, USA 
Potassium Chloride (KCl) Merck, Darmstadt, Germany 
Potassium Hydrogen phosphate (KH2PO4)  Merck, Darmstadt, Germany 
Proteinase K Roche Diagnostics, Basel, Switzerland 
Phytohaemagglutinin Sigma-Aldrich, St Louis, MO, USA 
Rabbit Serum (Normal) Dako, Glostrup, Denmark 
RAM-TRITC antibody Dako, Glostrup, Denmark 
Roswell Park Memorial Institute (RPMI) 1640 BioWhittaker, Walkersville, USA 
Sabax injection H2O LeBasi Pharmaceuticals, Potchefstroom, 
RSA Singlequots Lonza, Basel, Switzerland 
Sodium Acetate Merck, Darmstadt, Germany 
Sodium Chloride (NaCl) Merck, Darmstadt, Germany 
Sodium hydrogen phosphate (Na2HPO4)  Merck, Darmstadt, Germany 
Sodium Thiocyanate (NaSCN) Merck, Darmstadt, Germany 
Toluene Merck, Darmstadt, Germany 
Tris base Sigma-Aldrich, St Louis, MO, USA 
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Triton X-100  Sigma-Aldrich, St Louis, MO, USA 
Trypan blue  Sigma-Aldrich, St Louis, MO, USA 
Tween Merck, Darmstadt, Germany 
Vectashield with DAPI (4,6-diamidino-2-
phenylindole) 
Vector Laboratories, Burlingame, CA, 
USA Xylene Merck, Darmstadt, Germany 
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12 APPENDIX F: Equipment  
Axio Imager M1 microscope Carl Zeiss, Gottingen, Germany 
Centrifuge 5418 Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Cytospin 4 Thermo Scientific, Massachusetts, USA 
Drybath heating block  MRC, Holon, Israel 
Fume hood Erlab, Massachusetts, USA 
Gel Documentation System Minibis 
Pro 
DNR Bio-Imaging Systems Ltd, Jerusalem, Israel 
Haemocytometer Marienfeld-Superior, Lauda-Königshofen, Germany 
Incubator Direct Heat CO2 Thermo Scientific, Massachusetts, USA 
Laminar Flow Class II BSC Esco, Oregon, USA 
Light Microscope Prima Vert Carl Zeiss, Gottingen, Germany 
Medical Linear Accelerator Siemens Healthcare, Erlanger, Germany 
MyCycler Thermal Cycler Bio-Rad, California, USA 
Nanodrop 2000 spectrophotometer  Thermo Scientific, Massachusetts, USA 
Orbital shaker MRC, Holon, Israel 
pH meter Crison Instruments, Barcelona, Spain 
Powersupply Enduro 300V Labnet, New Jersey, USA 
QIAamp DNA Mini Kit  Qiagen, Venlo, Limburg, Netherlands 
Qiagen Multiplex PCR kit Qiagen, Venlo, Limburg, Netherlands 
Scale Adam Equipment, Milton Keynes, UK 
Waterbath Polyscience, Pennsylvania, USA 
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13 APPENDIX G: HPV Genotyping Primers 
Nishiwaki et al., 2008 
  Primer Sequence 
PPX6/F  GCTAAAGGTCCTGTTTCGAGGCGGCTA  
PPX6/R  GGCAGCGACCCTTCCACGTACAAT  
PPX11/F  GCGTGTTTTGCAGGAATGCACTGAC  
PPX11/R  TGCGTCTTGTTTGTCCACCTTGTCC  
PPX16U/F  TCCTGCAGGTACCAATGGGGAAGAGG  
PPX16U/R  TGCCATACCCGCTGTCTTCGCTTT  
PPX18/F  AACAGTCCATTAGGGGAGCGGCTGGA  
PPX18/R  TGCCGCCATGTTCGCCATTTG  
PPX31/F  GCGGTCCAAACGCTCTACAAAACGCACT  
PPX31/R  GCAGGGGCACCAACATCAACAATTCCA  
PPX33/F  ACACAGAGGCAGCCCGGGCATTGTTT  
PPX33/R  CACGGGTTTGCAGCACGATCAACA  
PPX35/F  CCATAACATCGGTGGACGGTGGACAGG  
PPX35/R  CCATTACATCCCGTCCCCTCCCCTTCA  
PPX39/F  CCGACGGAGTGTCCCTGGACCATCTTA  
PPX39/R  CCAGCGTTTTTGGTTCCCTTACCCCGTA  
PPX45/F  TGTTGGACATCACACCTACCGTGGA  
PPX45/R  TCCGTACCTGACCCAGAAGATGCAA  
PPX51/F  CAACTAGCAACGGCGATGGACTG  
PPX51/R  CTGCTTCGCGGGCTGACTAGAA  
PPX52/F  GGTGTTGGTGCTGGTGCTTTTGCTA  
PPX52/R  CAGTTACAGGGGGACGAATGGTGGA  
PPX56/F  TGTTGTTTTTCCGCCATTTTGTACATGCAACC  
PPX56/R  TGGCCTACATAGTGTATTCTGCAAGCCAAAAC  
PPX58/F GGTAGTACCCCACCGTCTGAGG 
PPX58/R AGACGTGACATTGCCACTGTCA 
PPX59/F  CCGAGCAAGACACCTAAGACAGCAACG  
PPX59/R  TCGGAGTCGGAGTCAGGTAATTGCT  
PPX66/F  GCGGGCGGCTCCTACCTCTTCCTCTTC  
PPX66/R  CCACCTAACCTGACACACACTGCCCAAGG  
PPXIS/F  TTATCCCGAGTCCCCCAGGCCTTTCT  
PPXIS/R  TGGCTTGGCCCCAACTTCCATCA  
 
